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The research presented in this study combines natural product chemistry with organic 
synthesis.  The natural product research involved a phytochemical investigation of a South 
African plant, Hypericum roeperianum, which belongs to the Hypericaceae (previously 
Clusiaceae/Guttiferae) family.  A combination of chromatographic techniques resulted in the 
isolation of two known compounds:  [3-(3,7-dimethylocta-2,6-dienyl)-2,4,6-
trihydroxyphenyl]phenylmethanone (3-geranyl-2,4,6-trihydroxybenzophenone) and 3-(1,1-
dimethyl-2-propenyl)-2-methoxy-6-phenyl-4H-pyran-4-one (hyperenone-A).  A third 
compound was also isolated and is provisionally assigned as 1-methoxy-5,5-dimethyl-1-
phenylhepta-1,6-diene-3,4-dione (39). However, the small amount of compound isolated did 
not provide sufficient data for a conclusive structural assignment. 
 
To the best of our knowledge 3-geranyl-2,4,6-trihydroxybenzophenone has not been isolated 
previously from the Hypericum genus but has been isolated from Tovomita krukovii, 
T. longifolia, Helichrysum monticola and Garcinia vieillardii.  It has been reported to exhibit 
inhibitory effects against Candida albicans, Candida neoformans, Staphylococcus a reus, 
Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella gallinarum and Mycobacterium 
smegmatis.  The activity exhibited against Mycobacterium smegmatis  of great interest as 
this bacterium belongs to the same genus as Mycobacterium tuberculosis, which is the 
bacterium that is the cause of tuberculosis (TB), a bacterial infectious di ease affecting 
1.7 billion people per annum.   
 
Due to the interesting biological activity exhibited by 3-geranyl-2,4,6-
trihydroxybenzophenone the synthetic section of our research involved the synthesis of this 
secondary metabolite as well as seven structural analogues.  These analogues, namely, phenyl-
[2,4,6-trihydroxy-3-(3-methylbut-2-enyl)phenyl]methanone, 1-[3-(3,7-dimethylocta-2,6-
dienyl)-2,4,6-trihydroxyphenyl]ethanone, 1-[2,4,6-trihydroxy-3-(3-methylbut-2-enyl)phenyl] 
ethanone, 1-[3-(3,7-dimethylocta-2,6-dienyl)-2,4,6-trihydroxy phenyl]-2-methylbutan-1-one, 
2-methyl-1-[2,4,6-trihydroxy-3-(3-methylbut-2-enyl)phenyl]butan-1-one, [3-(3,7-dimethylocta 
 iii  
-2,6-dienyl)-2,4,6-trihydroxyphenyl]-2-methylpropan-1-one, 2-methyl-1-[2,4,6-trihydroxy-3-
(3-methylbut-2-enyl)phenyl]propan-1-one, as well as 3-geranyl-2,4,6-trihydroxybenzo- 
phenone were successfully synthesized via a Friedel-Crafts acylation reaction of 
phloroglucinol with an appropriate acyl chloride.  Alkylation of the acyl phloroglucinol 
derivatives, with geranyl and prenyl moieties, was accomplished by Friedel-Crafts-type 
alkylation reactions. With the synthesis of these compounds we hoped to explore the 
significance of the structural features of 3-geranyl-2,4,6-trihydroxybenzophenone and 
determine whether variation in length of the prenyl side chain and the type of acyl group 
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Introduction and Aim of Study 
 
1.1 Plants as a Source of Medicinal Compounds 
 
Over a period of at least five thousand years, mankind has utilized natural products as its 
main source of medicinal compounds.1 In particular, plants on the African continent have a 
long history of medicinal use for various diseases and ailments.  These are of such 
importance that in some African countries, the majority of the population (up to 90%) still 
relies solely on plants for their healthcare.2  
 
Africa is known for its diverse range of flora, comprising of thousands of different species, 
many of which are indigenous to South Africa and are commonly used in traditional 
medicine to treat a range of diseases and illnesses.2,3  An investigation of these plants, 
selected on the basis of their use in traditional medicine, can lead to the discovery of 
potential new molecules with biological activity, which may have a significant influence 




Tuberculosis (TB) is a subject of great concern throughout the globe, but predominantly in 
poverty stricken Asia and Africa.4  This contagious airborne disease is caused by 
Mycobacterium tuberculosis.5 
 
It is statistically estimated that one third of theworld’s population (approximately 2 billion 
people) are hosts to the TB causing bacilli, resulting in 1.7 million deaths in 2006 (World 
Health Organization, 2008).4,6 
 
Although effective TB treatments are available, thedevelopment of multi-drug resistant 
strains (MDR-TB) as well as the co-prevalence of the human immunodeficiency virus 
(HIV) and TB has resulted in an urgent need for the discovery and implementation of 
 2 
novel anti-tuberculosis drugs, preferentially with alternative mechanisms of action.6  The 
potential use of natural products, or the derivatives thereof, has been previously mentioned 
and indicates that natural product chemistry may play a vital role in the discovery of 
innovative treatments for TB.  To substantiate thisclaim, recent research on (+)-calanolide 
A (1), isolated from Calophyllum lanigerum (Clusiaceae), has shown that this coumarin 
derivative inhibits Mycobacterium tuberculosis.7,8  Furthermore, this compound is not only 
active against the drug-susceptible strains, but has also been found to inhibit MDR-TB 
strains and in addition inhibits some strains of HIV.8  Calanolide A (1) exhibited promising 
results in phase I clinical trials, making it worthy for further investigation in phase II 
trials.9,10  Phase II trials were initiated, however the development of calanolide A is 
currently on hold, whilst awaiting a decision by the Sarawak government, who owns the 








The isolation of (+)-calanolide A (1), as well as many other biologically active compounds 
from the Clusiaceae family, prompted us to explore the phytochemistry of plants in South 
Africa belonging to this family. 
 
1.3 Thesis Aims 
 
The aim of the research presented in this study was to combine natural product research 
with organic synthesis.  This involved an investigation of a South African plant, 
Hypericum roeperianum, which belongs to the Hypericaceae (previously 
Clusiaceae/Guttiferae) family.  
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The major aims of this study were: 
•  To carry out a phytochemical investigation on H. roeperianum in order to identify 
some secondary metabolites present in the plant 
•  To examine the biological activity of the isolated compounds 
•  To synthesise a biologically active compound isolated from H. roeperianum 
•  To synthesise structural analogues (3 – 9) of the bio-active compound (2) 
(Figure 1.1) 
•  In the synthesis of these compounds we hoped to explore the significance of the 
structural features of the bioactive compound 2 and determine whether variation in 
length of the prenyl side chain and the type of acyl group present would affect the 


























Figure 1.1 The bioactive compound with the structural analogues. 
 4 
In this chapter we briefly presented the major concer s of TB and revealed how natural 
product chemistry may lead to the discovery of new potential drugs.  The aims of the 
project were also introduced.  In the following chapter we discuss the genus Hypericum.  
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An Overview of the Genus Hypericum  
 
2.1 Description and Distribution 
 
The genus Hypericum L. belongs to Hypericaceae, alternatively known as Clusiaceae or 
Guttiferae.1  Hypericum is a large genus comprised of approximately 400 species, which 
are widely distributed throughout the temperate regions of the world, though only one 
species occurs in South America, two in Australia and New Zealand and six (Hypericum 
revolutum, H. roeperianum, H. lalandii, H. aethiopicum, H. natalense, H. wilmsii) are 
indigenous to South Africa.2,3 
 
The Hypericum species vary from small trees and shrubs (up to 12 m tall) to herbs.3,4 
Although this genus is widely distributed, it is not present in habitats that are particularly 
dry, hot or cold and are rarely found in water.  The species that occur in the tropics are 
most commonly located at high altitude.  Thus Hypericum is seldomly found in deserts, 
polar regions and tropical lowlands.3,4 
 
Most species of Hypericum are recognizable by their characteristic leaves, flowers and 
fruit.3  The light-green leaves are simple (consisting of a single blade), oval in shape and 
arranged opposite to each other.  The leaves frequently contain glandular secretions which 
are evident as transparent, red or black spots.3  The translucent spots contain cells that 
secrete essential oils, whilst the red and black spots contain hypericin (10) or 
pseudohypericin (11).3 
 
The flowers (Figure 2.1) are comprised of green (occasionally red tinged) sepal  and a 
corolla containing five petals (rarely four), which are usually a shade of yellow varying 
from lemon-yellow to deep orange yellow.3,4  This yellow pigment (due to xanthones) is a 
common occurrence in the tissues of plants belonging to the Clusiaceae family.1,3  The 
inner whorls of the flower are comprised of pollen-producing stamens (3-5 groups) and an 











10:   R = H




Figure 2.1 The characteristic bright-yellow flowers of the Hypericum species:  
H. perforatum (top left),5 H. revolutum (top right)6 and H. roeperianum 
(bottom). 
 8 
Hypericum species bear capsular fruit (Figure 2.2) (most often dry), which splits open to 
release a copious amount of cylindrically shaped yellow-brown/purple-brown seeds.3  In 




Figure 2.2  Capsular fruit of H. perforatum.5 
 
2.2 Origins of the Name Hypericum 
 
Some attempts were made to derive the meaning of Hypericum from hypo or hyper-ericum 
suggesting that the name means beneath or above the heath.  However, the name 
Hypericum is thought to have originated from the ancient Greeks who named the plant 
νπερεικον (νπερ meaning ‘above’ and εικϖν  meaning ‘image’).3  This name arose as the 
ancient Greeks used Hypericum species to hang on their religious images to ward off evil 
spirits.3,7  In other regions the herb was referred to as fuga daemonum which translates to 
“make the demons flee”.  Evil presence was believed to be most intense on Midsummers 
Eve (23rd June – celebration of the pagan feast) and Halloween (31st October).  On these 
days of the year the Greeks emphasized the importance of safeguarding their religious 
images and homes by decorating them with Hypericum.3 
 
The name St. John’s Wort, which refers to the Hypericum species in general, but in most 
cases specifically to H. perforatum, came about during the Middle Ages when the pagan 
feast was Christianized and dedicated to Saint John the Baptist.  Traditionally, St. John’s 
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Wort was used to produce an anointing oil by infusing the herb in olive oil for a number of 
days.  This anointing oil was blood red in colour and allegedly symbolized the blood of the 
saint.8 In Old English the word “wort” meant “plant”.8 Today St. John’s Wort (more 
correctly Common St. John’s Wort) refers to H. perforatum, which is the species most 
commonly found in nearly all of Europe.3  The species name ‘perforatum’ is believed to be 
due to the translucent glandular dots present on the leaves of this plant, which when held 
toward light appear as though the leaves are perforated.7 
 
2.3 Traditional Uses of the Hypericum genus 
 
The traditional uses of the Hypericum species were mainly related to spiritual significan e, 
such as the protection from evil spirits as was previously mentioned.3,7  However, many 
members of the Hypericum genus were also used traditionally by ancient communities for 
treatment of various ailments, thus signifying the m dicinal value of this genus. 
 
Hypericum has been used therapeutically for thousands of years.  A Greek physician and 
botanist, Dioscorides, described its applications as a diuretic and in the treatment of nerve 
pain and malaria.8  The Japanese used H. chinense, indigenous to their country, to treat 
female abnormalities9 and in China, H. japonicum was used as a herbal medicine in the 
treatment of tumours, infectious hepatitis as well as some bacterial diseases.10,11  Native 
Americans used Hypericum as an abortifacient, anti-inflammatory, antiseptic, an astringent 
(substance that decreases the release of blood or mucus by constricting veins and body 
tissues)12 as well as in the treatment of kidney problems, nosebleeds, diarrhea, fever and 
colic.8,13,14 
 
H. perforatum (St. John’s Wort) is considered to have antibacterial, antiviral and anti-
inflammatory properties.8  In folk medicine this particular Hypericum species is recorded 
to have been used in various parts of the world as a remedy to a broad range of ailments.  
These include:  psychological disorders, insomnia, gastritis, nausea, kidney and respiratory 
problems, open wounds and burns.7,15 
 
Based on the evidence showing that Hypericum has been used medicinally for many 
centuries and has been recorded in the traditional ph rmacopoeia of several nations, its 
discovery by modern medicine is not unexpected.3 
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2.4    Biosynthesis of Classes of Compounds within the Genus  
 
Hypericum has been found to be an excellent source of a large range of compounds with 
the most active being of phenolic nature such as flvonoids, xanthones, phloroglucinol 
derivatives and naphthodianthrone structures.7  Some compounds have also been found to 






2.4.1 Phenolic Compounds 
 
Phenolic derivatives are characterized by the possession of one or more hydoxyl (OH) 
groups attached to an aromatic ring system.18  Phenol (13) is the simplest member of this 





Most phenolic derivatives originate from one or more f three building blocks, namely, 
acetyl co-enzyme A (14), erythrose-4-phosphate (15) and phosphoenol pyruvate (16) 
(Figure 2.3).19  The latter two molecules are both involved in the s ikimic acid pathway, 
whereas the acetate pathway relies on the presence of acetyl co-enzyme A (14) as well as 
















Figure 2.3 Three building blocks of common biosynthetic pathways. 
 
The biosynthesis of phenolic metabolites may be basd exclusively on the acetate pathway 
(e.g. phloroglucinol derivatives and anthrones), solely on the shikimic acid pathway (e.g. 
coumarins) or may involve a combination of these two pathways (e.g. flavonoids and 
xanthones).19,20  The biosynthesis of some phenolic metabolites will be reviewed in greater 
depth within this chapter. 
 
2.4.2 Phloroglucinol Derivatives 
 
Phloroglucinol derivatives are derived from 1,3,5-trihydroxybenzene (17).  Hyperforin 
(18)15, isolated from H. perforatum, is a phloroglucinol derived structure that has expanded 










Biosynthetically this class of compound arises solely from the acetate pathway.19 The 
building block, acetyl co-enzyme A (14), polymerizes to afford a chain of carbon atoms 
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where every alternate carbon has a keto function.  For this reason the acetate pathway may 
often be referred to as the polyketide pathway.  In order for polymerization to occur, acetyl 
co-enzyme A (14) is first converted into its more active form, malonyl co-enzyme A.  This 
is achieved through the addition of CO2, which is available to the plant through 
photosynthesis.  On condensation of the two molecules, the added CO2 is released.
19 
 
Scheme 2.1 shows the biosynthetic pathway of phloroacetophenon (19), where folding of 
the polyketide chain allows cyclization to occur via a Claisen reaction.  This involves the 
elimination of the thiol-leaving group, which in turn results in the formation of 
cyclohexatrione (20).  This intermediate transforms into the more stable aromatic form by 
keto-enol tautomerism affording the final product, phloroacetophenone (19), which 
possesses oxygen atoms on alternate carbons.  This distinctive oxygenation pattern is 




































Scheme 2.1  Biosynthesis of phloroacetophenone (19).20 
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Other acylphloroglucinols may be formed by changing the starter unit, e.g. the use of  
benzoyl-CoA (21), isovaleryl-CoA (22) or isobutyryl-CoA (23) in place of acetyl-CoA 
(14) will undergo the same mechanism to form 2,4,6-trihydroxybenzophenone[phenyl-
(2,4,6-trihydroxyphenyl)methanone] (24), 2-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-






























Coumarins (Figure 2.4) are phenolic compounds exhibiting a C6C3 backbone, which is 
cyclic in nature and referred to as a 2H-chromen-2-one system or by its older name 1,2-







Figure 2.4  Basic structure of coumarins. 
 
Para-coumaric acid is believed to be the significant precursor, which has to undergo two 
crucial steps in the process of forming coumarins (Scheme 2.3).19  Firstly, the aromatic 
ring must undergo hydroxylation ortho to the side chain to afford 2,4-dihydroxycinnamic 
acid.  The double bond present in the side-chain of this intermediate must then be 
converted from the trans-configuration to the cis-configuration.19,20  Due to the fact that the 
cis-configuration is less stable, it is thought that this transformation would be 
unfavourable.  Conversely, the conjugated system of cinnamic acid facilitates the 
isomerisation.20  Once the molecule is in the cis-configuration, cyclization can occur 
between the hydroxyl group and the carboxylic acid resulting in the formation of a lactone 
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Flavonoids, found abundantly in the plant kingdom, have a C6C3C6 skeleton, where the two 
aromatic rings (A and B rings) are joined by the C3 unit, which most often forms the 
C-ring.18,19  Several substructures (Figure 2.5) can be formed and are frequently described 
according to the degree of oxidation in the C-ring.  For instance, reduction of the flavones 












































Figure 2.5  Subclasses of flavonoids.25 
 
Many phenolic secondary metabolites, of which flavonoids are a good example, arise from 
the amalgamation of the two previously mention pathw ys (shikimic acid pathway and 
acetate pathway).20 In the initial biosynthesis of flavonoids, a polyketide is formed from a 
cinnamoyl-CoA building block (shikimate) where the chain has been extended by the 
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addition of malonyl-CoA units (acetate) (Scheme 2.4).  Folding of the polyketide allows a 
Claisen reaction to occur, which results in the formation of aromatic rings.  This step is 
catalyzed by an enzyme (chalcone synthase) and generat s chalcones, which are important 
precursors for a large number of flavonoid derivatives.20 
 
Flavanones are produced from the chalcone precursor via a Michael-type nucleophillic 
attack of the hydroxyl group on the α,β-unsaturated ketone moiety (Scheme 2.4).20  In 
turn, modifications of the simple flavanone skeleton, generally the pyran-4-one ring, may 
produce a variety of molecules including flavones, flavonols, anthocyanidins and flavan-3-
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*Various 2-oxogluterate-dependent oxygenases are required 
 





In chemical terms, the expression xanthone refers to compounds with a C6 1C6 carbon 
skeleton (27), where two benzene moieties are linked through a carbonyl group and an 
oxygen atom.  No free rotation of C-C bonds is possible as the rings are joined in a fused 
formation.  Various chemical groups may be attached to this backbone and these 







Xanthones, similarly to flavonoids, are derived from a combination of the shikimate and 
acetate pathways.19  A major difference in xanthone biosynthesis (Scheme 2.6) is that the 
shikimate starter unit is of the form C6 1 rather than C6C3 as evident in the biosynthesis of 
flavonoids.  Besides this difference the biosynthetic mechanism is comparable to that 








































Scheme 2.6 Biosynthesis of xanthones.19 
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2.4.6 Examples of Secondary Metabolites Isolated from Hypericum 
Species 
 
A large range of secondary metabolites have been prviously isolated from the Hypericum 
species.  Many of the isolated compounds are phenolic in nature and belong to the 
following classes: flavonoids, xanthones, phloroglucinol derivatives and 
acylphloroglucinols.  Some secondary metabolites have lso been found to possess a 
filicinic acid moiety. 
 









































































2.5 Biological Activity Associated with the Hypericum Species 
 
The genus Hypericum belongs to the Hypericaceae family, which is acknowledged to be a 
rich source of xanthones.  These xanthones exhibit various biological activities including:  
cytotoxic, mutagenic, anti-microbial, anti-tumour and anti-inflammatory effects.9,31  
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Xanthones isolated from the roots of H. roeperianum exhibited anti-fungal activity against 
Candida albicans.   
 
Phloroglucinol derivatives with biological activity have been isolated from H. uliginosum 
and H. brasiliense.16  The former exhibited anti-fungal activity against Trichophyton 
mentagrophytes, whilst the latter was found to have anti-bacterial activity against Bacillus 
subtilis.16  Furthermore, the extracts of H. brasiliense also showed inhibition of 
monoamine oxidases (MAO’s).  The regulation of some physiological amines depends on 
the MAO enzymes and thus the inhibition of these enzymes is considered to aid the control 
of depression.16 
 
Significant activity (values comparable or greater than streptomycin) against 
Staphylococcus aureus, B. subtilis and Mycobacterium smegmatis was exhibited by the 
hexane extracts of H. drummondii.  Isolation of the active compounds showed that the 
Gram-positive bacterial inhibition was due to filicini  acid derivatives.16,17,27 
 
2.5.1 Hypericum perforatum 
 
H. perforatum (St. John’s Wort) is by far the most studied species of the Hypericum genus.  
The aerial parts of this plant have been reported to contain:  Naphthodianthrones [hypericin 
(10) and pseudohypericin (11)], flavonoids, phloroglucinol derivatives [hyperforin (18)], 
coumarins, mono- and sesquiterpenes and phenolic carboxylic compounds.  The roots of 




Hypericin (4,5,7,4’,5’,7’-hexahydroxy-2,2’-dimethylnaphthodianthrone) (10) is a red 
pigmented anthroquinone derivative, which is one of the major active compounds isolated 
from H. perforatum.7  It has also been isolated from other Hypericum species, including 
H. hirustum, H. maculatum, H. nummularium and H. triquetrifolium.7  This photochemical 
compound is found in tiny glands located on the stem , leaves and flowers of the above 
Hypericum species, but is also present in some protozoa and insects.7  
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Hypericin (10) is a unique molecule containing both hydrophilic and hydrophobic 
regions.32  The large conjugated system is responsible for the photochemical properties of 
the compound.  The absorption of UV and visible rays b  the chromophore structure may 
result in photosensitivity if hypericin (10) is ingested in large enough amounts.8 
 
Originally, hypericin (10) was considered to be the active constituent responsible for the 
antidepressant properties exhibited by St. John’s Wort, however, upon further research 
hyperforin (18) was concluded to be the anti-depressant compound.26  Hypericin (10) is 
now often used as a detection standard in Hypericum extracts and as a marker compound 
specifically in H. perforatum.8,25 
 
Hypericin (10) and chemically similar, pseudohypericin (11) have been demonstrated to 
inhibit numerous retroviruses.  This antiviral activity has been tested by in vitro and in vivo 
studies, resulting in hypericin (10) exhibiting significant inhibition of the replication of 
viruses such as HIV, influenza A, Epstein-Barr virus, cytomegalo virus, human papilloma 
virus and herpes.8,32   
 
Mechanistically, the antiviral activity of hypericin (10) is unconventional in comparison to 
other known antiviral agents, as this naphthodianthro e compound inhibits the removal of 
the lipid sheath surrounding DNA and RNA viruses.32  By doing so, infected cells cannot 
release replicates of the virus.  This mechanism however, limits inhibition by 
hypericin (10) to viruses that contain membranes.  Future research of hypericin (10) could 




Hyperforin (18) is another major constituent of H. perforatum and is identified as being the 
compound associated with the plant’s antidepressant effects.14  Its phloroglucinol-derived 
structure is chemically incomparable to any other known antidepressant.14 
 
Biochemical studies indicate that this acylphloroglucinol derivative acts as an anti-
depressant by hindering the uptake of serotonin (5-HT), dopamine, norepinephrine and 
gamma-aminobutyric acid (GABA).  These neurotransmitters are responsible for 
conveying messages to and from the brain.  The lattr neurotransmitter, GABA, is involved 
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with the decrease of anxiety and the enhancement of relaxation.  Inhibition of these 
neurotransmitters results in accumulation of neurotransmitter levels in the brain, which in 
turn improves moods and re-establishes emotional stability.33 
 
Other than its effectiveness as an antidepressant, hyperforin (18) also possesses 
antibacterial activity against penicillin- and methicillin-resistant Staphylococcus aureus 
(MRSA) strains with outstanding MIC values of 0.1-1 µg ml-1.15   
This chapter gave an overview of the genus Hypericum, discussing various aspects of the 
genus.  The subsequent chapter covers the natural product section of our research, where 
we introduce H. roeperianum and present the findings of our phytochemical investigation 




1. A. Hutchings, A. Scott, G. Lewis and A. Cunningham.  Zulu Medicinal Plants, 
An Inventory.    University of Natal Press, South Africa, 1996, p. 203. 
2. D. J. B. Killick and N. K. B. Robson.  Clusiaceae, Flora of Southern Africa. 
1976, p. 14-23. 
3. E. Ernst.  Hypericum: The Genus Hypericum.  Taylor & Francis Ltd.  United 
Kingdom, 2003, p. 1-5. 
4. http://en.wikipedia.org/wiki/Hypericum  (Accessed on 22/09/2008). 
5. http://popgen.unimass.nl/.../Hypericum.perforatum.ht l  (Accessed on 
6/03/2009) 
6. http://www.botanic-garden.ku.dk/kic/Mpumalanga/images/image025.jpg 
(Accessed on 6/03/2009) 
7. C. A. J. Erdelmeier, E. Koch and R. Hoerr.  Hypericum perforatum – St. John’s 
wort chemical, pharmacological and clinical aspects.  Studies in Natural 
Product Chemistry, 2000, 22, 643-669. 
8. H. Cass.  All about St. John’s Wort.  Avery publishing group, New York. 1998. 
9. N.  Tanaka and Y.  Takaishi.  Xanthones from Hypericum chinense.  
Phytochemistry, 2006, 67, 2146-2151. 
 24 
10. K. Ishiguro, S. Nagata, H. Fukumoto, M. Yamaki, K. Isoi and Y. Yamagata.  A 
2-pyrone derivative from Hypericum japonicum.  Phytochemistry, 1994, 37, 
283-284. 
11. K. Ishiguro, S. Nagata, H. Fukumoto, M. Yamaki and K. Isoi.  Phloroglucinol 
derivatives from Hypericum japonicum.  Phytochemistry,  1994, 2, 469-471. 
12. E. B. Uvarov and A. Isaacs.  The Penguin Dictionary of Science.  Penguin 
Books Ltd, Middlesex. 1986, p. 26.  
13. http://en.wikipedia.org/wiki/St_John's_Wort  (Accessed on 24/09/08). 
14. http://www.associatedcontent.com/article/53238/st_johns_wort_actions_uses_a
nd_cautions.html  (Accessed on 24/09/08). 
15. S. Gibbons.  Anti-staphylococcal plant natural products.  Natural Product 
Reports, 2004, 21, 263-277. 
16. L. Rocha, A. Marston, O. Potterat, M. Auxiliadora, C. Kaplan, H. Stoeckli-
evans and K. Hostettmann.  Antibacterial phloroglucinols and flavonoids from 
Hypericum brasiliense.  Phytochemistry, 1995, 40, 1447-1452. 
17. H. Jayasuriya, A. M. Clark and J. D. McChesney.  New antimicrobial filicinic 
acid derivatives from Hypericum drummondii.  Journal of Natural Products, 
1991, 54, 1314-1320. 
18. R. Verpoorte and A. W. Alfermann.  Metabolic Engineering of Plant Secondary 
Metabolism.  Kluwer Academic Publishers, Boston.  2000, p. 5, 128. 
19. P. G. Waterman and S. Mole.  Analysis of Phenolic Plant Metabolites.  
Blackwell Scientific Publications, London.  1994, p. 9-10, 20-23. 
20. P. M. Dewick.  Medicinal Natural Products, A Biosynthetic Approach.  John 
Wiley & Sons Ltd., England.  2001, p. 61-63, 142-143, 149-151. 
21. http://www.siu.edu/~ebl/leaflets/articl.htm (Accessed on 24/09/08). 
22. H. Morita, Y. Takahashi, H. Noguchi and I. Abe.  Enzymatic formation of 
unnatural aromatic polyketides by chalcone synthase.  Biochemical and 
Biophysical Research Communications, 2000, 279, 190-195. 
23. K. W. M. Zuurbier, S-Y. Fung, J. J. C. Scheffer and R. Verpoorte.  Formation 
of aromatic intermediates in the biosynthesis of bitter acids in Humulus lupulus.  
Phytochemistry, 1995, 38, 77-82. 
24. G. P. Moss, P. A. S. Smith and D. Tavernier.  Glossary of class names of 
organic compounds and reactive intermediates based on structure.  Pure and 
Applied Chemistry, 1995, 67, 1307-1375. 
 25 
25. V. Cody, E. Middleton and J. B. Harborne.  Plant Flavonoids in Biology and 
Medicine.  Alan R. Liss, Inc., New York.  1987, p. 91. 
26. http://www.xango.com/science/xanthones  (Accessed on 16/01/09). 
27. H. Jayasuriya, J. D. McChesney, S. M. Swanson and J. M. Pezzuto.  
Antimicrobial and cytotoxic activity of rotterlin-type compounds from 
Hypericum drummondii.  Journal of Natural Products, 1989, 52, 325-331.  
28. M. L. Cardona and E Seoan.  Flavonoids and xanthonolignoids of Hypericum 
ericoides.  Phytochemistry, 1982, 21, 2759-2760. 
29. M. Tada, K. Chiba, T. Takakuwa and E. Kojima.  Analogues of natural 
phloroglucinols as antagonists against both thromboxane A2 and leukotriene D4.  
Journal of Medicinal Chemistry, 1992, 35, 1209-1212. 
30. W. K. P. Shiu and S. Gibbons.  Anti-staphylococcal acylphloroglucinols from 
Hypericum beanie.  Phytochemistry, 2006, 67, 2568-2572. 
31. G. Rath, O. Potterat, S. Mavi and K. Hostettmann.  Xanthones from Hypericum 
roeperanum.  Phytochemistry, 1996, 43, 513-520. 
32. http://www.delano.com/ReferenceArticles/Hypericin-Active.html (Accessed on 
24/09/08). 











3.1.1 Description and Distribution 
 
H. roeperianum Schimp. ex. A. Rich., (referred to as ‘Isivumelwane’ in Zulu) is one of the 
six Hypericum species indigenous to South Africa and occurs as a shrub or small tree 
ranging from 0.6 to 5 m in height (Figure 3.1.).1  As the stems age they become woody 
and flatten near the inflorescence.  This plant gives rise to bright-yellow flowers, which 
usually possess a number of dark marginal dots and co sist of five petals.2,3 
 
This plant grows in central, eastern and south tropical Africa, located in evergreen forests 
and bushland4,5.  It is commonly found growing near rivers or streams, usually at an 
altitude ranging between 1500 m and 2900 m above sea lev l.2 
 
Medicinally a root decoction of this particular species is drunk, either alone or in 
combination with various other plants, to cure female sterility.  However, nothing is known 
about the active constituents of the plant.4,5 
 
3.1.2 Previous Research on Hypericum roeperianum 
 
Research performed previously on H. roeperianum involved the isolation and 
characterization of ten xanthones (Figure 3.2) from the DCM extract of the roots of the 
plant.4  Spectroscopic techniques and chemical methods enabled the structures to be 
identified as 2-hydroxyxanthone (28), 5-hydroxy-2-methoxyxanthone (29), 1,5-dihydroxy-
2-methoxyxanthone (30), 2-deprenylrheediaxanthone B (31), isojacareubin (32), 
1,6-dihydroxy-5-methoxy-4’,5’-dihydro-4’,4’,5’-trimethylfurano[2’,3’:3,4]xanthone (5-O- 
methyl-2-deprenylrheediaxanthone B) (33), 1,6-dihydroxy-5-methoxy-3’,3’-dimethyl 
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pyrano[2’,3’:3,4]xanthone (5-O-methylisojacareubin) (34), calycinoxanthone D (35a), 
1,3,5,6-tetrahydroxy-4-trans-sesquilavandulylxanthone (35b) and 5-O-demethyl 




                                               Photo:  K. Smith 
 
Figure 3.1   H. roeperianum tree/shrub (top left) with a close-up view of the woody stem 
(top right) and opposite, simple leaves (bottom left).  The characteristic 





























(28) (29): R = H
(30): R = OH
(31): R = H
(32): R = Me
(33): R = H








Figure 3.2  Xanthones isolated from Hypericum roeperianum.4 
 
Xanthones 31 - 37 all possess a 1,3,5,6-oxygenation pattern, which is commonly found 
within the Clusiaceae family and compounds 31, 32, 34, 35a, 35b and 36 were found to 
exhibit antifungal activity against Candida albicans.4 
 
Crockett et al. analyzed the volatile constituents of the aerial parts of five Hypericum 
species.5  This resulted in the discovery that the major volatile constituent of 
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H. roeperianum is γ-curcumene (37).5,6  To the best of our knowledge no other previous 
work has been reported on the isolation of compounds from the aerial parts of H. 
roeperianum.  However, a number of compounds have been isolated from the leaves and 
stems of other Hypericum species.  H. chinense afforded xanthones from the MeOH 
extracts; flavonoids, naphthodianthrones and phlorog ucinol derivatives were isolated from 
the EtOAc extracts of H. perforatum and prenylated phloroglucinol derivatives were 




As indicated, the Hypericum genus has been found to be an excellent source of a large 
range of compounds, many of which exhibit useful bio ogical activities.4  Hence, interest in 
this particular genus has recently increased and future research may result in the discovery 
of potential drugs for various diseases and conditions.  For this reason, H. roeperianum 
was considered to be a suitable choice of plant to undergo phytochemical investigation.  
This selection was further validated by the fact that minimal research has previously been 
carried out on the aerial parts of this particular Hypericum species. 
 
3.2 Results and Discussion 
 
H. roeperianum was chosen for investigation on the basis that if a natural product is found 
to exhibit interesting therapeutic properties, it is often possible that another species 
belonging to the same genus (in the case of Hypericum) or family (Clusiaceae/ 




The current phytochemical investigation∗  resulted in the isolation of two known molecules 
(Figure 3.3):  3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-phenyl-4H-pyran-4-one  (38),     
and 3-geranyl-2,4,6-trihydroxybenzophenone {[3-(3,7-dimethylocta-2,6-dienyl)-2,4,6-
trihydroxyphenyl]phenylmethanone} (2).  A third compound was also isolated and is 
provisionally assigned as 1-methoxy-5,5-dimethyl-1-phenylhepta-1,6-diene-3,4-dione (39).  
However, the small amount of compound isolated did not provide sufficient data for a 










Figure 3.3 Isolated compounds. 
 
Compound 38 was previously isolated from the aerial parts of Hypericum mysorense and 
was named hyperanone A.9  To the best of our knowledge 39 has not been previously 
isolated, however, a compound with a similar structure has been isolated from Hypericum 
mysorense HEYNE.10  The compound isolated by Kikuchi et al.10 was named mysorenone-
C (40) and only differs from 39 by the presence of a hydroxyl group where 39 contains a 
methoxy moiety. 
 
                                               
∗  The phytochemical investigation of H. roeperianum was started by S. Mamode as an honours project in the 
School of Chemistry.  Although she has isolated some f the compounds, she has not determined the 






Compounds 38 and 39 exhibit very similar 1H NMR spectra.  In fact, the 1H NMR spectra 
show such a close resemblance that at first glance the spectra seem to be of the same 
compound.  When taking a closer look, it becomes evident that there are slight differences 
in the chemical shifts of certain signals (these will be described in greater depth in the 
structural elucidation of the two isolated metabolites (Section 3.2.1.1)).   
 
3.2.1 Structural Elucidation of Isolated Compounds 
 
The structures of the isolated metabolites were deduc  from NMR spectroscopy (1H, 13C, 
DEPT90, DEPT135, COSY, HSQC and HMBC experiments), UV-visible spectroscopy, 
IR-spectroscopy and electrospray mass spectrometry (ESIMS). 
 
3.2.1.1   Structural Elucidation of compounds 38  
 























The 1H NMR spectrum of 38 revealed two multiplets at δH 7.70 and δH 7.48, two doublets 
at δH 4.92 and δH 4.89, a doublet of doublets at δH 6.23 and three singlest at δH 6.61, 
δH 4.06 and δH 1.50. 
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The mulitplets appearing downfield δH 7.48 (3H, m) and δH 7.70 (2H) are characteristic of 
protons in an aromatic moiety.  The integration of these signals gives evidence that 
compound 38 contains a mono-substituted aromatic ring.  The multiplet integrating for 3H 
corresponds to the protons in the meta and para positions, whilst the signal at δH 7.70  
integrates for 2H and is assigned to the protons in the ortho positions of the aromatic ring.  
The signals observed at δC 125.5, δC 129.1 and δC 130.9 in the 13C NMR spectrum were 
assigned as the ortho, meta and para methine groups, respectively.   
 
The UV spectra of compound 38 showed a maximum absorption at 277 nm (log ε 3.63), 
which confirms that a conjugated aromatic chromophore is present within the structure. 
 
The two doublets and the doublet of doublets observed in the 1H NMR spectrum suggest 
the presence of an alkene.  The correlation of these signals to a methylene and methine 
carbon in the 13C NMR spectrum as well as the integration of the signals in the 1H NMR 
spectrum implies that the alkene is terminal (i.e. a vinyl moiety). 
 
The 1H NMR spectrum shows the doublet of doublet appearing at δH 6.23 (1H, J = 10.7 
and 17.6 Hz, correlating to δC 148.3).  The coupling constant of 10.7 Hz is characteristic of 
coupling between two cis-olefinic protons.  The doublets resonating at δH 4.89 and δH 4.92 
have coupling constants of 10.8 Hz and 17.5 Hz, respectively and correlate to δC 108.3 in 
the 13C NMR spectrum.  As already mentioned, the former coupling constant is 
characteristic of coupling between two cis-olefinic protons.  The latter coupling constant 
(17.5 Hz) is commonly observed in the coupling of two trans-olefinic protons.  This 
information leads us to conclude that the alkene present within the structure is most likely 








Figure 3.4 Type of alkene present in the structure of 38. 
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The upfield singlet observed in the 1H NMR spectrum at δH 1.50 correlated to the signal at 
δC 27.5 in the 13C NMR spectrum.  The DEPT90 and DEPT135 data enabled the singlet to 
be assigned as a methyl group.  The signal in the 1H NMR spectrum integrates for 6H 
suggesting that there are two overlapping methyl moieties present within the structure. The 
sharp singlet at the δH 4.06 (3H, correlating to δC 56.0 in the HSQC) occurs in the region 
characteristic of methoxy groups. 
 
The signals of the 13C NMR spectrum for 38 appearing downfield at δC 181.2 and δC 162.7 
signify the inclusion of a carbonyl functional group, specifically a ketone, within the 
structure as well as the presence of an olefinic carbon attached to a methoxy group. 
 
The interpretation of the acquired data, reveals that t e following fragments appear in the 









Figure 3.5 Fragments of compounds 38. 
 
Conclusions were drawn based on the connection of the ragments, which was established 
by the long range C-H couplings exhibited by the HMBC spectroscopy experiments.  The 
spectral data therefore illustrated that 38 was 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-
phenyl-4H-pyran-4-one (hyperanone A).  
 
The ESIMS [M+H]+ data obtained for compound 38 showed a molecular ion peak at 
m/z 271.331 [M+H]+, which was in agreement with a calculated value of 271.1334 for 
C17H19O3.  This evidence as well as the relatively good correlation of 38 in comparison to 











H                     
(Int., Mult., J/Hz) Assignment 
2 162.7   
Carbon in pyrone ring on 
which the methoxy group is 
attached 
3 111.6   
Carbon in pyrone ring on 
which the carbon side chain 
is attached 
4 181.2   Carbonyl C 
5 111.3 6.61 (1H, s) CH in pyrone ring 
6 156.8   
Carbon in pyrone ring on 
which the aromatic ring is 
attached 
7 56.0 4.06 (3H, s) Methoxy group 
1' 130.9   
Aromatic carbon attached to 
pyrone ring 
2', 6' 125.2 7.70(2H, m) 
2 x CH in ortho positions of 
aromatic ring 
3', 5' 129.1 7.48 (3H, m) 
CH's in meta positions of 
aromatic ring 
4' 130.9 7.48 (3H, m) 
CH in para position of 
aromatic ring 
1" 38.8   
Quaternary carbon in alkyl 
chain 
2" 148.3 
6.23 (1H, dd, J = 10.7, 
17.5) 
CH of alkene 
3" 108.3 
4.89 (1H, d, J = 10.8)     
4.92 (1H, d, J = 17.5)     
CH2 of the alkene 
4", 5" 27.5 1.50 (6H, s) 








3.2.1.2 Provisional Structural Elucidation of Compound 39 
Refer to the NMR data for 39 (Plates 2.1 – 2.7 and Table 3.2).  
 
Due to the small amount (2 mg) of compound 39 isolated, the NMR data was obtained 
from a very dilute solution resulting in poor quality spectra, thus making the signals 























As in compound 38, the 1H NMR spectrum for compound 39 exhibited two multiplets 
(δH 7.60 and δH 7.41), two doublets (δH 5.27 and δH 5.24), a doublet of doublets (δH 6.17) 
and three singlets (δH 6.31, δH 3.75 and δH 1.48). 
 
The multiplets at δH 7.60 (2H) and δH 7.41 (3H) were respectively assigned to be the 
methine groups in the ortho positions and meta and para positions of a mono-substituted 
aromatic ring.  The HSQC showed these signals correlating to δC 126.0 (ortho positions), 
129.0 (meta positions) and and δC 131.3 (para position) in the 13C NMR spectrum.  The 
presence of the aromatic ring was confirmed by the UV data which showed a maximum 
absorption band at 276 nm (log ε 3.46).  The band occurring at this wavelength is 
characteristic of a conjugated aromatic chromophore. 
 
The two doublets and the doublet of doublets observed in the 1H NMR spectrum suggest 
the presence of an alkene.  The correlation of these signals to a methylene (δC 116.2) and 
methine (δC 140.1) carbon in the 13C NMR spectrum as well as the integration of the 
signals in the 1H NMR spectrum implies that the alkene is terminal (i.e. a vinyl moiety). 
 
The 1H NMR spectrum shows the doublet of doublets appearing at δH 6.17 (1H, J = 10.6 
and 17.8 Hz). The doublets resonating at δH 4.89 and δH 4.92 have coupling constants of 
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10.8 Hz and 17.5 Hz.  As previously mentioned, these coupling constants are characteristic 
of coupling between two cis-olefinic or trans-olefinic protons.  This information leads us 
to conclude that a terminal alkene is present within e structure of the compound 39. 
 
The singlet appearing at δH 1.48 in the 1H NMR spectrum integrated for 6H and was 
assigned to two methyl moieties (DEPT90 and DEPT135 showed that this signal was a 
methyl group).  The HSQC showed a correlation betwen the singlet at  δH 1.48 in the 
1H NMR spectrum and δC 23.5 in the 13C NMR spectrum, whilst the HMQC spectrum 
showed long-range C-H coupling between the singlet at  δH 1.48 and the following signals 
in the 13C NMR spectrum: δC 140.1, δC 48.6 and δC 195.5.  The latter two signals are not 
observed in the 13C NMR spectrum as the sample was too dilute, but δC 48.6 is assigned as 
the quaternary carbon to which the two methyl groups are attached and the signal at δC 
195.5 is assigned as a carbonyl functional group.  The fact that the methyl moieties link to 
δC 140.1 suggests that the methyl groups are in close proximity to the methine group of the 
terminal alkene. 
 
The sharp singlet at the δH 3.75 (3H, correlating to δC 51.7 in the HSQC occurs in the 
region characteristic of methoxy groups.  The methoxy moiety correlates to δC 163.8 in the 
HMBC.  This signal is assigned as the quaternary cabon to which the methoxy group is 
attached. 
 
The spectral data allowed 39 to be provisionally assigned as 1-methoxy-5,5-dimethyl-1-
phenylhepta-1,6-diene-3,4-dione.  In order to achieve a conclusive elucidation of 39, the 
compound would need to be re-isolated to obtain a gre ter amount and hence attain better 















H                     
(Int., Mult., J/Hz) Assignment 
1 163.8   
Carbonyl on which the 
methoxy group is attached 
2 106.8 6.31 (1H, s) 
CH of alkene adjacent to a 
carbonyl C 
4 195.5   Carbonyl groups 
5 48.6   
Quaternary carbon in alkyl 
chain, to which two methyl 
groups are attached 
6 140.1 
6.17 (1H, dd, J = 10.4, 
17.4) 
CH of terminal alkene 
7 116.2 
5.24 (1H, d, J = 10.8)     
5.27 (1H, d, J = 17.5)     
CH2 of the alkene 
8 51.7 3.75 (3H, s) Methoxy group 
9, 10 23.5 1.48 (6H, s) 
2 x methyl groups on alkyl 
chain 
2', 6' 126.0 7.60 (2H, m) 
2 x CH in ortho positions of 
aromatic ring 
3', 5' 129.0 7.41 (3H, m) 
CH's in meta and para 
positions of aromatic ring 
4' 131.3 7.41 (3H, m) 
CH's in meta and para 













3.2.1.3 Structural Elucidation of Compound 2  
 



























The 1H NMR spectrum revealed a multiplet at δH 7.58 (5H) indicating that an aromatic 
group is present in the structure.  This is further substantiated by the appearance of the 
signals in the 13C NMR spectrum resonating in the δC 125 – 135 region.  The integration 
observed in the 1H NMR spectrum suggests that the aromatic substituen  is mono-
substituted.  The existence of alkenes was established by the presence of signals resonating 
at δH 5.27 (1H, t, J = 7.0 Hz) and δH 5.05 (1H, t, J = 7.0 Hz) in the 
1H NMR spectrum, 
which correlated to the signals at δC 123.7 and δC 121.5 in the 
13C NMR spectrum, 
respectively. 
 
The signal in the 13C NMR spectrum appearing downfield at δC 197.7 is characteristic of a 
ketone (C-7), whilst the quartenary carbon observed at δC 170.9 is commonly assigned to 
carbon atoms attached to hydroxy groups within a phenolic ring (C-2, C-4, C-6).  A singlet 
was also observed at δH 10.31, which was assigned to the hydroxyl hydrogens.  Hydroxyl 
groups that are hydrogen bonded characteristically appear in this region as they are highly 
deshielded by the close proximity of the electronegative atom.  In the structure of 
compound 2 the hydrogen bonding occurs between the hydrogen atoms of the phenol 
groups and the oxygen atom of the carbonyl moiety.  The three singlet three-proton peaks 
(δH 1.80, δH 1.67 and δH 1.59) resonating furtherest upfield in the 
1H NMR spectrum, are 
due to the presence of three methyl groups. 
 
From the above information we can conclude that each of the following fragments 











Figure 3.6 Fragments of compound 2.
 
The assignments of the chemical shifts of the protonated carbons were allocated on the 
basis of HSQC and COSY NMR spectroscopy experiments.   
 
The COSY experimental data shows that the triplet at δH 5.27 couples to the doublet at 
δH 3.38 (2H, J = 7.0 Hz), as well as to the broadened singlet at δH 1.80, which has been 
assigned as a methyl group.  This indicates that the proton atoms responsible for the 
appearance of these three signals are in close proximity to one another.  
 
 The NMR experiments therefore indicate that compound 2, isolated from H. roeperianum, 
is 3-geranyl-2,4,6-trihydroxybenzophenone.   
 
The UV-visible spectrum of 2 exhibited a maximum absorption band at 309 nm 
(log ε 3.68).  This is indicative that a conjugated system is incorporated in the structure of 
the compound.  The IR spectrum of 2 showed a prominent, sharp peak at 1710 cm-1, which 
is characteristic of absorption by a ketone moiety.  The existence of phenol groups is 
evident by the appearance of a broad band at 3316 cm-1.  The peak at 1605 cm-1 suggests 
that compound 2 contains a carbon-carbon multiple bond, more specifically an alkene.  
The peak at 700 cm-1 substantiates the presence of an alkene as peaks observed in this 
region are characteristic of the absorption arising from carbon-hydrogen bending vibrations 
of an alkene.  Thus, the information retrieved from the UV-visible data and IR spectra 
validates that the compound isolated from Hypericum roeperianum is 3-geranyl-2,4,6-
trihydroxybenzophenone {[3-(3,7-dimethylocta-2,6-dienyl)-2,4,6-trihydroxyphenyl] 
phenylmethanone} (2) as was elucidated from the NMR data.   The electrospray mass 
spectrometry data further confirms this structure, as a molecular ion peak was observed at 
m/z 365.1758 [M-H]-, which was in agreement with the calculated value for C23H25O4. 
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Table 3.3 NMR data of compound 2. 
 
Carbon C 
H                    
(Int., Mult., J/Hz) Assignment 
1 104.6   
Carbon on phenolic ring to 
which the acyl group is attached 
2, 4, 6 170.9   
Carbons attached to phenol 
groups 
3 108.5   
Carbon on phenolic ring to 
which the alkyl chain is attached 
5 96.3 5.94 (1H, s) CH in penolic ring 
1’ 197.7   Carbonyl C 
2' 140.1   Carbon of aromatic ring 
3', 4', 
5', 6', 7’  
127.9-
129.1 
7.62 (5H, m) Aromatic protons 
1 " 21.5 3.38 (2H, d, J = 7.0) 
CH2 in alkyl chain, adjacent to 
phenolic ring 
2" 121.5 5.27 (1H, t, J = 7.0) CH of alkene 
3" 135.1   
 Quaternary C in alkyl chain on 
which methyl group is attached 
4" 39.7 2.05 (2H, m) CH2 in centre of chain 
5" 26.4 2.08 (2H, m) 
CH2 adjacent to terminal alkene 
of chain 
6" 123.7 5.05 (1H, t, J = 6.9) CH of terminal alkene 
7" 132.2   
Quaternary C in alkyl chain on 
which terminal methyl groups 
are attached  
8"* 25.6 1.67 (3H, s) Terminal methyl group 
9" 16.2 1.80 (3H, s) 
Methyl group on alkene closest 
to phenolic ring 
10"* 17.7 1.59 (3H, s) Terminal methyl group 
 
* Assignment may be interchanged 
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3-Geranyl-2,4,6-trihydroxybenzophenone (2) was previously isolated from Tovomita 
krukovii, T. longifolia, Helichrysum monticola, H. spathulatus, H. squarrosus and 
Garcinia vieillardii.11,12,13,14,15 It has been found to exhibit inhibitory effects against 
Candida albicans, C. neoformans, Staphylococcus aureus, S. aureus methicillin resistant 
strain, Klebsiella pneumoniae, Salmonella gallinarum and Mycobacterium smegmatis.11,12  
It has also been revealed that 2 is biologically active as an antileishmanial agent against 
Leishmania mexicana and L. infantum.15  Hay et al. have deduced that the geranyl 




Two known compounds were isolated from H. roeperianum: 3-(1,1-dimethyl-2-propenyl)-
2-methoxy-6-phenyl-4H-pyran-4-one (38) and {[3-(3,7-dimethylocta-2,6-dienyl)-2,4,6-
trihydroxyphenyl]phenylmethanone} (2).  A third metabolite was isolated and was 
provisionally assigned as 1-methoxy-5,5-dimethyl-1-phenylhepta-1,6-diene-3,4-dione (39). 
However the elucidation of the structure of this comp und is not certain due to insufficient 
material.  Compounds 38 (hyperanone A) and 2 have been isolated previously from other 
plant sources. 
 
In this study, 3-geranyl-2,4,6-trihydroxybenzophenone (2) was isolated for the first time 
from the Hypericum genus, although it has been isolated previously from Garcinia 
vieillardii , Tovomita krukovii and T. longifolia, all of which originate from the Clusiaceae 
family.11,12,15  Inhibitory effects against various microbes are reported for compound 2, of 
which the antimicrobial activity against Mycobaterium smegmatus i  of great interest, as 
this bacterium belongs to the same genus as Mycobaterium tuberculosis, which is the 
bacterium that is the cause of tuberculosis (TB).11,12,15  Further investigation of this 
compound or compounds with related structures may therefore lead to the discovery of a 
potential drug for the treatment of tuberculosis.  Thus, the synthetic section of our research 
incorporated the synthesis of 2 as well as the synthesis of seven structural analogues of this 
compound. 
 
As 2 was isolated from the DCM leaf extract and was found to have interesting activity, as 
indicated above, we decided to discontinue the phytochemical investigation of the 
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remaining plant extracts and focus on the synthesis of this bioactive compound and 
derivatives thereof.  Further investigation of the plant extracts, especially of the more polar 




3.4.1 Standard Experimental Techniques 
 
3.4.1.1 Thin-layer Chromatography (TLC) 
 
Qualitative thin-layer chromatography (TLC) was carried out on Macherey-Nagel 
aluminium sheets or glass plates, coated with a 0.20 mm layer of silica gel 60 with a 
fluorescent indicator UV254.  After development, the plates were viewed under UV light 
before being sprayed with anisaldehyde.  The hexane solv nt refers to a mixture of hexane 
isomers. 
 
3.4.1.2 Flash Column Chromatography 
 
Flash column chromatography was performed on glass columns (of various diameters) 
containing Merck silica gel 60 (230 – 400 mesh, particle size:  0.040 – 0.063) to a height 
ranging from 8 cm to 15 cm.  The silica gel was loaded into the column as a slurry, using 
an appropriate solvent system, which was to be the eluting system for that particular 
column.  The plant extract or fraction was dissolved in the appropriate solvent and 
carefully loaded on the surface of the silica gel.  In some cases the fraction was absorbed 
onto silica gel before being loaded onto the column.  Further solvent was applied and the 
column was allowed to elute as fractions were colleted.  The elution of the column was 
performed under pressure (compressed air). 
 
3.4.1.3 The Chromatotron 
 
The chromatotron is a type of thin-layer chromatograph, which is centrifugally accelerated.  
Solutions of compounds to be separated were applied to chromatotron plates of either 
2 mm or 4 mm depending on the mass of the sample.  The chromatotron plates were 
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prepared from Merck silica gel 60 PF254 containing gypsum.  The separation was 
conducted on a Harrison Research chromatotron (model 7924T), where elution with a 
suitable solvent (found using TLC) by gravity flow forms concentric bands of separated 
compounds.  A UV lamp is used to detect the UV active bands, making the concentric 
bands more visible and easier to collect. 
 
3.4.1.4 Anisaldehyde Stain Reagent 
 
Thin-layer chromatograms were stained with an anisaldehyde solution (13 mL) mixed with 
concentrated sulfuric acid (17 mL), glacial acetic a id (5 mL) and absolute ethanol 
(465 mL).  The plates were subsequently heated witha eat gun to an approximate 
temperature of 100 °C in order to ensure the optimum development of colour. 
 
3.4.1.5  Instrumentation 
 
NMR spectra were recorded on a Varian Unity Inova 500 or a Bruker 400 spectrometer.  
1H NMR and 13C NMR spectra were referenced to residual protonated solvent signals and 
deuterated solvent signals, respectively.  Coupling constants were calculated in Hertz (Hz).  
The following abbreviations were used when describing the multiplicities of the peaks 
observed in the 1H NMR spectra: 
 
Abbreviation    Peak Multiplicity  
 s   singlet 
 d   doublet 
 dd   doublet of doublets 
 t   triplet 
 m   multiplet 
 
Infrared spectra were recorded on a Bruker Alpha FT – IR spectrometer.  Mass spectra 
were obtained either on a Thermofinnigan Trace gas chromatograph coupled to a Polaris Q 
ion trap electron impact mass spectrometer (GC-EIMS) or on a Waters Acquity liquid 
chromatograph linked to a Waters LCT Premier time-of-flight mass spectrometer 
(electrospray ionization in either positive or negative mode).  UV-visible absorption 
spectra were obtained using a Varian Cary 50-Probe UV-visible spectrometer.  Melting 
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points of crystalline compounds were determined by use of a Kofler hot-stage melting 
point apparatus. 
 
3.4.2 Plant Preparation and Extraction of Hypericum roeperianum 
 
3.4.2.1 Collection and Preparation of Plant Material 
 
The H. roeperianum Schimp. ex. A. Rich plant material was collected from the 
Pietermaritzburg National Botanical Gardens, KwaZulu-Natal, South Africa on the 
5 February 2007.  The plant was identified by Isabel Johnson and voucher specimen 
[K. Smith 1 (NU)] deposited at the Bews herbarium (Nu), UKZN, Pietermaritzburg).  The 
plant material was separated into leaves and stems and left to dry at room temperature for a 
period of two weeks.  The stems were cut into smaller pieces in order to facilitate the 
milling of the material.  The leaves and stems were ground separately by use of a hammer 
mill. 
 
3.4.2.2 Extraction of Plant Material  
 
The ground leaves of the plant (556 g dry material) were extracted using DCM (3.0 L) at 
room temperature for 44 h.  The plant material was removed by vacuum filtration and the 
solvent evaporated by use of a rotary evaporator, to yield 22.9 g of extract.  The same 
leaves were then extracted sequentially with DCM and MeOH in a 1:1 ratio giving a total 
volume of solvent of 2.2 L.  This extraction commenc d for twenty-four hours and yielded 
50.0 g of extract.  A further sequential extraction was carried out using MeOH (2.2 L) as 
the solvent.  The twenty-four hour extraction yielded 44.6 g of extract. 
 
The dried stems (520 g) were extracted initially with DCM (2.0 L) for a period of 24 hours.  
The solvent-containing extract was separated from the remaining stems by gravity 
filtration and thereafter the solvent was removed by use of a rotary evaporator. This 
process yielded 3.88 g of extract.  A sequential extraction was carried out with 
DCM:MeOH (1:1) (1.8 L).  The plant material was extracted for 24 h and gave rise to 
7.08 g of extract.  The next extraction was performed over a 24 h time period with MeOH 
and yielded a sticky brown extract (3.25 g).  
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Thin-layer chromatography (TLC) was used to analyse compounds present within the 
extracts.  A number of solvent systems were used to elute the TLC plates until a suitable 
system was found, and hence could be used to further separate the compounds either by 
use of a chromatotron or by column chromatography. 
 
3.4.3 Isolation of Compounds from the DCM Crude Leaf Extract  
 
3.4.3.1 Fractionation of Extract 
 
The DCM extract was eluted with the solvent system Hex:EtOAc (4:1) and was viewed 
under UV light and thereafter with the anisaldehyde stain.  Nine spots were observed and 
appeared to be relatively well separated (Table 3.4). 
 
Table 3.4   TLC results of the Crude DCM Leaf Extract eluted with Hex:EtOAc (4:1). 
Description 
  Rf value 
No Agent UV Active Anisaldehyde 
Stain 
1 0.02 - -  Orange 
2 0.09 Yellow  - Green 
3 0.14 -  Yes  - 
4 0.21 Green -  Sea-green 
5 0.26  - Yes  - 
6  0.32  - -  Purple 
7  0.40  -  - Purple 
8 0.56  -  - Blue-Purple 
9 0.74 Yellow  - Purple 
 
The DCM Extract (4.97 g) was dissolved in DCM and loaded onto a column and eluted a 
solvent system of Hex:EtOAc in a ratio of 4:1.  The polarity of the solvent system was 





The column was finally washed with 100% MeOH.  Eighty-seven fractions (ca. 10 mL) 
were collected.  These were spotted on a TLC plate which was eluted with 
Hex:EtOAc (1:1) solvent system and viewed under UV light followed by anisaldehyde 
stain reagent.  This showed that a relatively good separation of compounds had been 
obtained.  The fractions were appropriately combined into nine fractions, namely A to I 
(Table 3.5). 
 
Table 3.5 Fractions obtained from the column separation of the Crude DCM Leaf Extract 
of H.  roeperianum. 
  Fractions 
Combined 
Mass (mg) Description 
A 1 - 14 1170 Yellow-green, sticky 
B 15 - 29 149 Army green 
C 30 - 40 167 Army green 
D 41 - 60 604 
Dark green, almost 
black, sticky 
E 61 -70 393 
Dark green, almost 
black, sticky 
F 71 - 74 448 
Dark green, almost 
black, sticky 
G 75 - 78 195 Dark green 
H  79 - 85  167  Dark brown, sticky 
I  86 - 87  57 




3.4.3.2 Isolation of 1-Methoxy-5,5-dimethyl-1-phenylhepta-1,6-diene-3,4-dione (39) 
 
Purification of fraction D (Table 3.5) (0.60 g) by column chromatography using a solvent 
system comprised of Hex:EtOAc (1:1) gave rise to 45 fractions (ca. 10 mL), which were 
combined to give a total of 8 fractions (39A – 39G).   The column (3 cm in diameter) was 
packed as a slurry (height of silica gel = 12 cm) and on progression of the column the 
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polarity of the solvent system was increased by using 100% EtOAc and finally washing 
with MeOH.   
 
 
Table 3.6  Masses of combined fractions obtained on Purification of Fraction D. 
 
  Fractions Combined Mass (mg) 
39A 1 - 7 4 
39B 8 - 12 2 
39C 13 - 15 3 
39D 16 - 18 3 
39E 19 - 21 2 
39F 22 -33 7 
39G 34 - 39 7 
39H 40 - 45 345 
 
Proton NMR spectra were run on the 8 combined fractions.  This process yielded a 
relatively pure fraction, 39B (Table 3.6), which was further analysed by NMR. 
 
1-Methoxy-5,5-dimethyl-1-phenylhepta-1,6-diene-3,4-dione (39) was obtained as a 
colourless oil (2 mg).  UV (DCM) λmax (log ε):  276 (3.46) nm;  IR νmax:  3396, 2920, 
2852, 1719, 1645 cm-1;  1H NMR (400 MHz, CDCl3): δH 1.48 (3H x 2, s, H-9, H-10), 3.75 
(3H, s, H-8), 5.24 (1H, d J = 10.8 Hz, H-7), 5.27 (1H, d, J = 17.5 Hz, H-7), 6.17 (1H, dd, 
J = 10.6 and 17.8 Hz, H-6), 6.31 (1H, s, H-2), 7.41 (3H, m, aromatic protons, H-3’, H-4’, 
H-5’), 7.60 (2H, d, aromatic protons, H-2’, H-6’);  13C NMR (400 MHz, CDCl3): δC 23.5 
(C-9, 10), 48.6 (C-5), 51.7 (C-8), 106.8 (C-2), 116.2 (C-7), 126.0 (C-2’, 6’), 129.0 






3.4.3.3 Isolation of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-phenyl-4H-pyran-4-one 
(38) 
 
Fraction E (Table 3.5) (390 mg) was dissolved in DCM (5 ml) and loaded onto a column 
(3 cm in diameter) which had been previously packed as a slurry (height of silica gel: 
12 cm) and initially eluted with Hex:EtOAc (1:1).  The polarity of the solvent system was 
gradually increased during the progression of the column, making use of 100% EtOAc and 
thereafter washing with MeOH.  This resulted in the collection of 40 fractions, which were 
further analysed by TLC and hence similar fractions were combined.   
 
Table 3.7 Masses of combined fractions obtained on Purification of Fraction E. 
 
  Fractions Combined Mass (mg) 
41A 1 - 9 5 
41B 10 - 13 6 
41C 14 - 16 2 
41D 17 - 18 124 
41E 19 - 24 3 
41F 25 - 26 1 
41G 27 - 31 1 
41H 32 - 40 5 
 
It was evident by proton NMR spectroscopy that fraction 41E (Table 3.7) was pure.  This 
fraction was thus subjected to further NMR analysis. 
 
3-(1,1-Dimethyl-2-propenyl)-2-methoxy-6-phenyl-4H-pyran-4-one (38) was obtained as a 
colourless oil (3 mg).  UV (DCM) λmax (log ε):  277 (3.63) nm; IR νmax: 1709, 1420, 1358, 
1220, 1093, 902, 528, 454, 391 cm-1; 1H NMR (CDCl3, 500 MHz): δH 1.50 (3H x 2, s, 
H-4”, H-5”), 4.06 (3H, s, H-7), 4.89 (1H, d, J = 10.8 Hz, H-3”), 4.92 (1H, d, J = 17.5 Hz, 
H-3”), 6.23 (1H, dd, J = 10.7 and 17.6 Hz, H-2”), 6.61 (1H, s, H-5), 7.48 (1H x 3, t, 
aromatic protons, H-3’, H-4’, H-5’), 7.70 (1H x 2, d, aromatic protons, H-2’, H-6’).  
13C NMR; (CDCl3, 500 MHz): δC 27.5 (C-4”, 5”), 38.8 (C-1”) 56.0 (C-7), 108.3 (C-3”), 
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111.3 (C-5), 111.6 (C-3), 125.2 (C-2’, 6’), 129.1 (C-3’, 5’), 130.9 (C-1’, 4’), 148.3 (C-2”), 
156.8 (C-6), 162.7 (C-2), 181.2 (C-4); ESIMS:  m/z 271.1331 [M + H]+ (calculated for 
C17H19O3, 271.1334)  
 
3.4.3.4 Isolation of 3-geranyl-2,4,6-trihydroxybenzophenone (2) 
 
Combined Fraction G (Table 3.6) was spotted on TLC plates and eluted with various 
solvent systems.  The solvents system Hex:EtOAc (1:1) showed optimal separation of the 
evident spots and hence a column was run on sample G using this solvent system.  
Sample G (0.132 g) was loaded onto a column (3 cm in diameter, height of silica gel was 
11 cm), which had been packed as a slurry.  On progression of the column the polarity of 
the solvent was increased, using 100% EtOAc and finally washing with MeOH.  A total of 
41 fractions (ca. 8 mL) were collected, analysed by TLC (eluted with Hex:EtOAc (1:1), 
viewed under UV and with anisaldehyde stain) and appro riately combined (10 fractions 
were obtained).   
 
Table 3.8  Masses of combined fractions obtained on Purificat on of Fraction G. 
 
  Fractions Combined Mass (mg) 
24A 1 - 3 8 
24B 4 - 5 4 
24C 6 - 9 51 
24D 10 - 12 25 
24E 13 - 14 6 
24F 15 - 19 6 
25A 20 - 26 15 
25B 27 - 32 9 
25C 33 - 37 6 
25D 38 - 41 43 
 
Proton NMR spectra on the combined fractions showed that Sample 24C (Table 3.8) was 
relatively pure and hence this fraction was further analysed by NMR.  
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3-Geranyl-2,4,6-trihydroxybenzophenone (2) was obtained as a green oil (51 mg).  UV 
(DCM) λmax. (log ε):  309 (3.68) nm;  IR νmax: 3317, 2927, 1710, 1605, 1431, 1327, 1292, 
701 cm-1; 1H NMR (CDCl3, 400 MHz): δH 1.59 (3H, s, H-10”), 1.67 (3H, s, H-8”), 1.80 
(3H, s, H-9”), 2.05 (2H, m, H-4”), 2.08 (2H, m, H-5”), 3.38 (2H, d, J = 7.0 Hz, H-1”), 5.05 
(1H, t, J = 6.9 Hz, H-6”), 5.27 (1H, t, J = 7.0 Hz, H-2”), 5.94 (1H, s, H-5), 7.62 (5H, m, 
H-Ar); 13C NMR (CDCl3, 400 MHz): δC 16.2 (C-9”), 17.7 (C-10”), 21.5 (C-1”), 25.6 
(C-8”) 26.4 (C-5”), 39.7 (C-4”), 96.2 (C-5), 104.6 (C-1), 121.5 (C-2”), 123.7 (C-6”), 
127.9-129.1 (C-3’ – C-7’), 132.2 (C- 7”), 140.0 (C-2’), 170.9 (C-2, C-4, C-6), 197.9 (C-1);  
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The aim of this research was to synthesize the isolated phloroglucinol derivative, 3-
geranyl-2,4,6-trihydroxybenzophenone ([3-(3,7-dimethylocta-2,6-dienyl)-2,4,6-trihydroxy-
phenyl]phenylmethanone) (2), as well as 7 structural analogues of this compound 
(Figure 4.1).  In synthesizing these molecules, we hoped to explore the significance of the 
structural features of 2 and determine whether variation in the length of the prenyl side 
chain and the type of acyl group present, would affect the activity against Mycobacterium 
smegmatis. 
 
Prior to the commencement of synthetic procedures, a thorough literature survey was 
performed.  The aim of this was, not only to establish whether the target compounds had 
been previously synthesized or isolated from natural p oduct sources, but also to gain 
insight to methods and synthetic reactions reported in literature that may be useful in our 
approach to the synthesis of the desired analogues.   
 
To the best of our knowledge, analogues 3 and 5 have not been isolated from natural 
sources, however, the remaining analogues (4, 6 – 9), as well as the parent compound (2), 
have all been isolated previously (Table 4.1).  Compounds 2, 6, 8 and 9 are all known to 
exhibit biological activity. 
 
The activity exhibited by 2 has been discussed in Chapter 3 (Section 3.2.1.2).  Both 
compounds 6 and 8 are reported to inhibit COX-1 (cyclooxygenase-1), exhibiting IC50 
values of 26.2 and 6.0 µM, respectively.1  In addition, compound 8 also inhibits COX-2 
(cyclooxygenase-2) with an IC50 value of 29.9 µM.  COX-1 and COX-2 are enzymes that 
are involved in the prostaglandin pathway.2  More specifically, the COX enzymes 
metabolize arachidonic acid to prostaglandin H2, which in turn is the substrate that leads to 
the production of prostaglandins and thromboxane.  Prostaglandins play a significant role 
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Figure 4.1 The bioactive compound with the structural analogues. 
 
Both 6 and 8 also exhibited activity against the enzyme, which catalyzes the first step of 
leukotriene synthesis, 5-lipoxygenase (5-LOX).1  Compound 6 was reported to have an 
IC50 value of 5.8 µM, whilst the value reported for 8 was slightly lower (IC50 2.2 µM).  
Crockett et al.1 thus concluded that lengthening of the side chain metato the geranyl group 
significantly reduces the effect on the bioactivity against COX-1, but only minimally 
reduced the activity against 5-LOX. 
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Analogue 9 is reported to exhibit significant antimicrobial activity against the following 
microbes:  Enterococcus faecalis (IC50 7.8 µM), Staphylococcus epidermis (IC50 9.8 µM), 
S. aureus (IC50 6.3 µM), S. aureus (methicillin and gentamycin resistant) (IC50 7.8 µM) 
and Bacillus cereus (IC50 7.8 µM).3  Activity was also observed against Pseudomonas 
aeruginosa (IC50 45.0 µM), Cryptococcus neoformans (IC50 26.0 µM) and Candida 
albicans (IC50 23.8 µM), however, the IC50 values are notably higher than those reported 
for the previous list of microbes.3   
 
The literature thus illustrates that prenylated acylphloroglucinol derivatives possess potent 
biological activity against various microbes as well as against enzymes within the 
prostaglandin and leukotriene pathways. 
 
An in depth investigation of literature revealed that the bioactive compound 2 as well as 
analogues 3 – 5 and 8 – 9 have been synthesised previously.  No synthetic routes to 
compounds 6 and 7 were described; we therefore believe that this is the first report where 
compounds 6 and 7 have been achieved by synthetic procedures. 
 
Brajeul et al.4 reported a synthesis of 2,4,6-trihydroxy-3-prenylbenzophenone (phenyl-
[2,4,6-trihydroxy-3-(3-methylbut-2-enyl)phenyl]methanone) (3) and a compound similar to 
2 (differing only in the presence of a methoxy moiety para to the geranyl side chain 
instead of a hydroxyl group).  Their synthetic approach involved a nucleophilic 
substitution reaction which resulted in the addition of prenyl or geranyl groups to 2,4,6-
trihydroxybenzophenone and its trimethyl ether by the use of previously prepared 
tetrafluoroborate sulfonium salts.  This method result d in the formation of the prenylated 










Table 4.1. Plants from which compounds 2, 4 and 6 – 9 have been isolated. 
Compd Species Family Activity  









Active against:  Leishmania 




Staphylococcus aureus and 
S. aureus methicillin 
resistant strain.8 
4  Melicope ptelefolia10 Rutaceae    
Achyrocline alata11 Asteraceae 
Esenbeckia nesiotica12 Rutaceae 
Helichrysum stenopterum13 Asteraceae 
6 
Hypericum empetrifolium1 Clusiaceae 
COX-1 and 5-LOX 
inhibition.1 
Helichrysum 
        gymnocomum14 7 
Helichrysum infaustum15 
Asteraceae   
Achyrocline alata11 Asteraceae 










COX-1,COX-2 and 5-LOX 
inhibition.1 
Helichrysum gymnocomum3 
Helichrysum infaustum15 9 
Helichrysum platypterum16 
Asteraceae 
Active against: Enterococcus 
faecalis, S. epidermis, 
S. aureus, S. aureus 
methicillin and gentamicin 
resistant strain, Bacillus 
cereus, Pseudomonas 
aeruginos, Cryptococcus 
neoformans and C. albicans.3 
 
 
Prior research has established that C-prenylation and C-geranylation can be achieved via a 
nucleophilic substitution reaction in which acylated phloroglucinol derivatives are reacted 
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with either prenyl or geranyl bromide in the presence of a base such as potassium 
carbonate or sodium hydride.16,19,20  This method has afforded analogues 4, 5, 8 and 9 with 
yields ranging from 28% to 40%.  These relatively low yields are considered to be due to 
the formation of multiple products formed by polyalkylation.  Furthermore, O-alkylation 
may also occur instead of the desired C-alkylation. 
 
Interestingly, Tan et al.21 synthesised a compound similar to 2,4,6-trihydroxy-3-
prenylacetophenone (1-[2,4,6-trihydroxy-3-(3-methylbut-2-enyl)phenyl]ethanone) (5) 
(differing only in the presence of a methoxy group para to that of the prenyl side chain) 
where they utilized the more easily achieved O-alkylation reaction followed by a Claisen 
rearrangement followed by a Cope rearrangement to afford the C-alkylated product 
(Scheme 4.1).21  This five-step synthetic approach attained good yields per individual step 
(63%, 91%, 80%, 86% and 75% respectively, for bis-protection of phloroacetophenone 






































Scheme 4.1  Synthesis of C-alkylated product via O-alkylation21 
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The high yields obtained at each step, especially those of the O-prenylation and Claisen 
rearrangement, suggest that this synthetic strategy may be preferable in comparison to the 
direct C-alkylation, although the latter approach is advantageous as the number of steps 
involved is reduced from four (excluding methylation) to one. 
 
4.2 Results and Discussion 
 
4.2.1 C-Prenylation via O-alkylation followed by Claisen/Cope 
Rearrangement 
 
This synthetic approach was adapted from the method reported by Tan et al.21 and is a 
four-step reaction sequence involving protection, O-prenylation, consecutive Claisen and 
Cope rearrangements and lastly deprotection (Scheme 4.2).     
 
The initial step of the synthetic strategy involves selective protection of two of the three 
hydroxyl groups of phloroacetophenone (19).  This step ensures that the subsequent O-
alkylation is restricted to a specific free hydroxyl group.  Protection with MOMCl, as 
reported by Tan et al.21 was not considered owing to the fact that this reagent is highly 
carcinogenic and is not commercially available.  Benzyl ether protection and methylation 





















Scheme 4.2  Proposed four-step synthesis of 2,4,6-trihydroxy-3-prenylacetophenone (5). 
 58 
Bisbenzylated phloroacetophenone (1-(2,4-Bis-benzyloxy-6-hydroxyphenyl)ethanone) (41) 
was successfully obtained in 70% yield (Scheme 4.3). This was achieved by dissolving 
three equivalents of K2CO3 and one equivalent of phloroacetophenone (19) in dry DMF.  
Two equivalents of benzyl chloride (BnCl) was added an  the reaction mixture was heated 
to 80 °C.  The reaction was quenched, by adding 1 M HCl, after a time period of 2.5 h.  
The 1H NMR spectrum for this compound revealed a multiple  at δH 7.40 (10H) in the 
region characteristic to that of aromatic protons.  This multiplet correlated to the peaks in 
the region δC 127.6 – 128.7 in the 13C NMR spectrum.  These signals were assigned to the 
two mono-substituted aromatic rings of the benzyl ether protecting groups.  The methylene 
groups of the protecting group were observed as a singlet (δH 5.06, 4H) in the 1H NMR 
spectrum and appearing at δC 70.3 and δC 71.1 in the 13C NMR spectrum.  The methyl 
moiety of phloroacetophenone (19) was observed as a singlet in the 1H NMR spectrum 
resonating at δH 2.55 and integrating for three protons. 
 
The 1H NMR also revealed a singlet at δH 13.99 (1H) as well as two doublets at δH 6.10 
(1H, J = 2.3 Hz) and δH 6.16 (1H, J = 2.3 Hz).  The downfield singlet (δH 13.99) arises due 
to the proton of the unprotected hydroxyl group, which forms a hydrogen bond with the 
oxygen of the ketone.  This ketone is observed in the 13C NMR spectrum as a quaternary 
carbon at δC 203.1.  The doublets in the 1H NMR spectrum are characteristic of the two 
meta-aromatic protons of phloroacetophenone derivatives.  Quaternary carbons were also 
observed in the 13C NMR spectrum at δC 162.0, 165.1 and 167.6, which were assigned to 
the three oxygenated aromatic carbons. 
 
The NMR data thus gave evidence that our compound obtained was the desired 
bisbenzylated phloroacetophenone (41).  This conclusion was confirmed by the EIMS data, 
which revealed a molecular ion peak at m/z 371.1262 [M+Na]+, which was in agreement 
with the calculated value for the sodium adduct of the molecular formula C22H20O4Na. 
 
The tribenzylated phloroacetophenone (42) was obtained as a by-product in a yield of 28%. 
This compound was recognized by the aromatic signal in the 1H NMR spectrum (δH 7.38), 









































Scheme 4.3  Synthesis of 2,4,6-trihydroxy-3-prenylacetophenone (5). 
 
As was expected, the reaction favoured the bisbenzylated product 41 over the tribenzylated 
product 42, which was only obtained in a low yield.  This is attributed to the presence of 
the acyl group and the O-hydroxy groups in phloroacetophenone (19), which can form an 










Figure 4.2 Intramolecular bonding of phloroacetophenone (19). 
 
This intramolecular H-bond is stabilized due to theconjugated double bonds occurring 
between the donor (oxygen atom of hydroxy group) and cceptor (oxygen atom of the 
carbonyl group) atoms (Figure 4.2).22  This effect is referred to as “resonance-assisted 
hydrogen bonding” by Bertolasi et al.23  The delocalisation of the π-electrons results in the 
C=O and C=C weakening as their electrons are shared amongst the C-O and O-H bonds, 
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which in turn shorten as they gain partial double bond character.24  Furthermore, the 
conformation of the acyl group and the position of intramolecular bond is also sterically 
favoured as the closing of the H-bond forms a six-membered ring.22  Thus, due to the 
strength and stability of this H-bond, it is difficult for the proton of the hydroxy group to be 
abstracted by a base (e.g. K2CO3 or NaH) and replaced by a protecting group.  Therefore, 
as anticipated, the tribenzylated product 42 is not favoured and is consequently obtained in 
poor yields. 
 
Protection by methylation to form bismethylated phloroacetophenone (43) was also 
attempted but very low yields (1 – 4%) were achieved and therefore this route 








Scheme 4.4 Methylation of phloroacetophenone (19). 
 
The second step involved O-alkylation of the bisbenzylated phloroacetophenone (41) with 
prenyl bromide (3,3-dimethylallyl bromide).  In this step a base was used to deprotonate 
the remaining unprotected hydroxy group, forming a phenoxide ion.  The phenoxide ion 


















Scheme 4.5 O-Alkylation of 1-(2,4-bis-benzyloxy-6-hydroxyphenyl)ethanone (41).  
 
This reaction was carried out using either NaH or K2CO3 as the base and various solvents, 
namely acetone, DMF and THF.  In the reactions where NaH was used, yields of 45% and 
54% were obtained in THF and DMF, respectively.  When deprotonating with K2CO3, the 
DMF reaction was unsuccessful and the reaction in acetone only yielded 34% of 
O-alkylated product (44).  In an attempt to increase this yield, dibenzo-18-crown-6 (45) 











Dibenzo-18-crown-6 (45) is a crown ether whose central cavity coordinates particularly 
well with potassium cations.  Thus, the addition of this compound assists in the dissolution 
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of K2CO3 into organic solvents and hence enables the base to r act more efficiently in 
deprotonating the free hydroxy group. 
 
CuI was added to act as a catalyst in converting the prenyl bromide to the more reactive 
prenyl iodide via halogen exchange. 
 
The O-prenylated adduct, 1-[2,4-bis-benzyloxy-6-(3-methylbut-2-enyloxy)phenyl] 
ethanone (44), was converted to the para C-prenylated derivative via a thermal Claisen 
rearrangement, also known as the [3,3]-sigmatropic rearrangement (Scheme 4.6), followed 
by a Cope rearrangement.  This was achieved by refluxing 44 in N,N-dimethylaniline. 
 
This type of rearrangement is concerted in nature, meaning that the one bond forms and the 
other breaks at the same time.  This results in the formation of the unstable keto tautomer 
as an intermediate.25  The keto tautomer rapidly undergoes a proton shift, transforming into 


































Scheme 4.6 Mechanism of Claisen/Cope rearrangement.25 
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The Claisen/Cope rearrangement reaction was successful in achieving the desired para 
C-prenylated product (46) (Plates 4.1 and 4.2), although a by-product was also present.  
This by-product, 1-[4,6-bis-benzyloxy-3-(1,1-dimethylallyl)-2-hydroxyphenyl]ethanone 
(47) (Plates 4.1 and 4.2), was obtained by the Claisen rearrangement, which was not 
followed by the Cope rearrangement.  These two compounds were obtained in a 50:50 
mixture, each with a yield of 28.5%.  An attempt to purify and separate these compounds 
(which appeared at the same Rf value) by TLC and column chromatography was 








Due to the poor yields achieved in the Claisen/Cope rearrangement, it was decided to 
attempt the one-step C-alkylation reaction of phloroacetophenone (19) with prenyl 
bromide.   In spite of the low yields reported in lterature, this synthetic strategy is 
advantageous as the number of steps involved, is reduced from four to one.   
 
Another synthetic route investigated, was the introduction of the alkyl group via a directed-
ortho metallation (DOM) type reaction.  This strategy would require all the hydroxyl 
groups present to be protected.  Starting with the acetophenone precursors may make the 
protection of all three hydroxyl moeities difficult to achieve in good yield due to the 
intramolecular H-bonding that occurs within these types of molecules as discussed 
previously.  For this reason, we proposed phloroglucinol (17) as the starting material and 
protected the hydroxyl groups with the benzyl ether protecting group.  The reaction was 








The 1H NMR data for 48 showed a multiplet in the aromatic region (δH 7.40), which 
integrated for 15 protons, thus indicating the presence of the three mono-substituted rings 
of the benzyl ether protecting groups.  Furthermore, th  1H NMR spectra also revealed 
singlets at δH 5.03 and δH 6.31, integrating for six and three protons, respectiv ly.  The 
former was assigned to the three CH2 groups of the benzyl ether protecting groups, whilst 
the latter was assigned to the three methine protons present on the unsubstituted carbons of 
the phloroglucinol ring. 
 
The yield of 46% obtained for the tribenzylated phloroglucinol (48) was not very 
promising for the first step of this synthetic route, hus we decided to attempt the direct 
C-alkylation method before continuing with this synthetic strategy. 
 
 
4.2.2 Acylation of Phloroglucinol in the Synthesis of Target Compounds 
 
In order to synthesize the isolated phloroglucinol derivative 2 and the structural analogues 
(3, 6 - 9), an acylation reaction is required using the appropriate acyl chloride in each case.  
For analogues 2 and 3, commercial benzoyl chloride was used.  The acyl chlorides, 
2-methylbutyryl chloride and isobutyryl chloride, required for the synthesis of analogues 
6 - 7 and 8 – 9, are also commercially available, however, their rspective carboxylic acids 
(2-methylbutyric acid and isobutyric acid) are more stable and therefore have a longer 
shelf life and are also much less expensive.  For these reasons 2-methylbutyryl chloride 
and isobutyryl chloride were prepared by a nucleophilic addition-elimination reaction 
between their respective carboxylic acids and an inorganic acid chloride.  Phosphorous 
trichloride (PCl3), phosphorous pentachloride (PCl5) and thionyl chloride (SOCl2) are 
common inorganic acid chlorides known to give high yields of acyl chlorides when reacted 
with carboxylic acids.25  We used SOCl2, which reacted with the respective carboxylic 
acids to form a protonated acyl chlorosulfite interm diate (Scheme 4.7).  This intermediate 
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is highly reactive as its acyl constituent is a better leaving group compared to that of the 
acyl chloride.25 
 
The gases released as by-products of the reaction were bubbled through H2O and hence 
entrapped.  The acyl chloride was then obtained by distillation.  Isobutyryl chloride 
distilled at 92 °C, which agreed with the literature value (91-93 °C) quoted for the boiling 
point of this compound.26  2-Methylbutyryl chloride was collected at a temperature of 
112 °C.  This temperature is slightly lower than the value of 117 – 121 °C as stated in 
literature.26  As 2-methylbutyric acid and SOCl2 have boiling points of 176-177 °C 26 and 
79 °C 26 respectively, which differ substantially from that expected for the acyl chloride, 
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The two prepared acyl chlorides and the commercial benzoyl chloride were reacted with 
phloroglucinol (17) to form three aryl ketones (24 - 26) (Figure 4.3) via a Friedel-Crafts 
acylation reaction (Scheme 4.9).  The acylation reactions were performed using various 
methods in order to achieve the highest possible yields.  The methods differed in the 
reaction temperature as well as in the solvent (DCM/nitrobenzene) and lewis acid 
(AlCl 3/ZnCl2) that was used.  The method where phloroglucinol ad aluminium trichloride 
were dissolved in nitrobenzene and refluxed with the appropriate acyl chloride at 80 °C 
was observed to achieve the highest yields.  This method resulted in compounds 24, 25 and 















(24) (25) (26)  
 
Figure 4.3 The three prepared aryl ketones.  
 
The Friedel-Crafts acylation reaction is an electrophilic aromatic substitution reaction 
where most often the electrophile is an acylium ion (acyl cation).  This acylium ion is 
created when the Lewis acid catalyst (commonly AlCl3) forms a complex with the acyl 
halide and abstracts the halide atom, resulting in the formation of a resonance stabilized 































































Scheme 4.9 Mechanism of the acylation reaction.25 
 
4.2.2.1 Structural Elucidation of Compounds 24 - 26 
 
The prepared acyl phloroglucinol derivatives 24 (Plates 5.1 and 5.2), 25 (Plates 6.1 and 
6.2) and 26 (Plates 7.1 and 7.2) were fully characterized by NMR (1H, 13C, DEPT90, 
DEPT135, COSY, HSQC and HMBC) spectroscopy, ultraviolet spectroscopy (UV), 


















The molecular mass of 2,4,6-trihydroxybenzophenone [phenyl-(2,4,6-
trihydroxyphenyl)methanone] (24) was confirmed by ESIMS where a peak was observed 
at m/z  253.0473 [M+Na]+, which agrees the calculated value for C13H10O4Na, the sodium 
adduct of the molecular formula.  The UV spectrum of 24 exhibited a maximum absorption 
band at 306 nm (log ε 4.36).  This indicated that a conjugated system is incorporated in the 
structure of the compound.   
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The 13C NMR spectrum (Table 4.2) (Plate 5.2) showed only 9 of the 13 expected signals 
and therefore it was concluded that 4 pairs of signals were overlapping.  The appearance of 
the methine signals resonating in the δC 125-140 region suggested the presence of an 
aromatic group.  This was confirmed by the signals (δH 7.36, 7.45, 7.58) corresponding to 
the para, meta and ortho protons in the 1H NMR spectrum, thus signifying that the 
aromatic ring was unsubstituted. 
 
The signals occurring at δC 143.1, 164.0, 166.1 and 200.8 in the 13C NMR spectrum were 
assigned to quarternary carbons, as there was no evidence of these signals in the DEPT 
experiments.  The latter signal is characteristic of a carbonyl moiety, whilst those 
resonating at 164.0 and 166.1 are characteristic of arbons attached to hydroxyl groups 
within a phenolic ring.  This implied that our struct re contained a phloroglucinol moiety.  
As only two signals were observed in this region, it is expected that two of the three C-OH 
groups of the phloroglucinol ring will be in a similar environment and thus these signals 
will overlap to show only one peak.  Further confirmation of the presence of a 
phloroglucinol moiety was the appearance of the broad band observed in the region 
3000-3500 cm-1 in the IR spectrum, which is characteristic of alcohol groups, specifically 
hydrogen-bonded phenols.  The IR spectrum also show a sharp peak in the region where 
carbonyl functional groups are observed (1635 cm-1). 
 
Other than the aromatic protons, the 1H NMR spectrum (Plate 5.1) also revealed a sharp 
singlet (2H, δH 5.81).  The HSQC experiment showed that this signal correlated to δC 96.0 
in the 13C spectrum, and were assigned to be the protons on the two unsubstituted carbons 
of the phloroglucinol ring. 
 
The long-range 13C-1H couplings observed in the HMBC spectrum enabled the correct 
connection of the fragments to be established.  The experimental data therefore indicates 







Table 4.2  NMR data for 24 
Carbon C 
H                        
(Int., Mult., J/Hz) HMBC Correlation 
1 106.1     
2,6 164.0     
3,5 96.0 5.81 (2H, s) 
C-1, C-1', C-4,        
C-2, C-6 
4 166.1     
1' 200.8     
2' 143.1     
3',7' 129.4 7.58 (2H, d, J = 7.4) C-1' 
4',6' 128.8 7.36 (2H, t, J = 7.4) C-2' 
5' 132.2 7.45 (1H, t, J = 7.4) C-4', C-6' 
 
 
The 13C NMR data acquired for 25 and 26 (Table 4.3) (Plates 6.2 and 7.2, respectively), 
was similar to that of 24 in regards to the carbonyl moiety (δC 211.6 and 211.9, 
respectively) as well as the carbons in the phenolic ring on which the hydroxyl groups are 
attached which were observed at δC 166.0 and 165.8, respectively.  The HSQC experiment 
shows that the signal resonating at δC 96.1 in each spectrum correlates to a singlet at δH 
5.82 (2H) in the 1H NMR spectrum.  As with 24, the signals mentioned denote the 
presence of a carbonyl group, a phloroglucinol ring and the latter are assigned as the 






















The 1H NMR spectrum for 26 (Plate 7.1) shows a doublet at δH 1.12 (6H), which is 
recognized to be the two methyl groups of the isopropyl fragment of the acyl 
phloroglucionol derivative.  This signal was found to correlate to δC 19.8 in the 13C NMR 
spectrum.  The 1H NMR spectrum of 26 also revealed a heptet at δH 3.97 (1H, J = 6.7 Hz).  
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The HMBC experiment showed long range C-H coupling of this methine signal to the two 
methyl groups, as well as coupling between the methyl groups and the carbonyl moiety.  
This resulted in the full characterization of our isopropyl constituent which is attached to 
our carbonyl group, which in turn is the substituent o  our monosubstituted phloroglucinol 
ring. 
 
The elucidation of the structure of 26 was substantiated by the experimental data obtained 
from ESIMS, UV-vis and IR spectroscopy.  A molecular ion peak of m/z 219.0633 
[M+Na]+ was observed on the ESIMS spectrum, which agrees th  calculated value for 
C10H12O4Na.  The UV-vis data confirmed the presence of conjugated bonds in the structure 
by the exhibition of absorption bands at 229 nm (log ε 4.60) and 287 nm (log ε 4.73).  The 
IR spectrum of 26 showed a prominent peak at 1570 cm-1 and a broad band in the region of 
3000 – 3500 cm-1, the former is characteristic of a ketone moiety whilst the broad band 
gives evidence of phenolic groups.   
 
Compound 25 exhibited a triplet (δH 0.89, 3H, J = 7.4 Hz) and a doublet (δH 1.10, 3H, 
J = 6.7 Hz) which were assigned to be methyl groups attached to a methylene and methine 
carbon, respectively.  In the 1H NMR spectrum (Plate 6.1), the two methylene protons 
were not equivalent and appeared as two multiplets resonating at δH 1.36 and δH 1.80 with 
an integration of one proton each.  This observation is attributed to the diastereotopic 
relationship of the methylene protons due to the adjacent stereocentre.  The HSQC 
experiment showed that these protons correlated with the carbon resonating at δC 28.3 in 
the 13C NMR spectrum and the HMBC showed long range C-H coupling to the two methyl 
groups, the carbonyl function and the methine group.  The latter proton appears at δH 3.85 
(1H, J = 6.7 Hz) in the 1H NMR spectrum and correlates to the carbon resonating  δC 46.8 
in the 13C NMR spectrum.  Further investigation of the HMBC experiment aided in 
establishing the connection pattern of all the fragments present, resulting in the conclusion 
that compound 25 was the desired 2-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one.   
 
The UV-vis data acquired for 25 displayed two absorption bands at 228 (log ε 4.52) and 
288 (log ε 4.68) which confirmed the presence of a conjugated system within the structure 
of the compound.  This was further substantiated by the broad band observed at 3206 cm-1 
in the IR spectrum denoting the presence of a phenolic substituent.  The IR data also gave 
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evidence of a ketone group (1567 cm-1).  ESIMS revealed a molecular ion peak 









Table 4.3 NMR data of compounds 25 and 26 
 
  Compound 25 Compound 26 
Carbon δC 
δH                       
(Int., Mult., J/Hz) 
HMBC 
Correlation δC 
δH                       
(Int., Mult., J/Hz) 
HMBC 
Correlation 
1 211.6     211.9     
2 46.8 3.85 (1H, sextet, J = 6.7) 
C-1, C-3,     
C-4, C-5 
40.0 3.97 (1H, heptet, J = 6.7) C-3, C-4  
28.3 1.36 (1H, multiplet) 
C-1, C-2,     
C-4, C-5 
3 
28.3 1.80 (1H, multiplet) 
C-1, C-2,     
C-4, C-5 
19.8 1.12 (6H, d, J = 6.7) C-1, C-2 
4 12.5 0.89 (3H, t, J = 7.4) C-2, C-3 19.8 1.12 (6H, d, J = 6.7) C-1, C-2 
5 17.3 1.10 (3H, d, J = 6.7) 
C-1, C-2,     
C-3 
-     
1' 105.5     104.8     
2',4',6' 166.0     165.8     
3',5' 96.1 5.81 (2H, s) 
C-1', C-2',     
C-4', C-6' 
96.1 5.82 (2H, s) 




4.2.3 Direct C-alkylation of Acylated Phloroglucinol Derivatives  
 
The fact that we were unable to obtain a pure product from the method adapted from Tan 
et al.,21 as well as the low yields obtained (Section 4.2.1), prompted us to investigate 
alternative routes to the desired product and its analogues.   
 
The literature review revealed that the direct introduction of the prenyl side chain may be 
problematic.  This may be attributed to the lack of control over regioselectivity, 
chemoselectivity and the occurrence of polyalkylation.27,28  A further concern is that prenyl 
moieties have the ability to cyclize and hence often orm closed ring structures.29   
 
We attempted to alkylate phloroglucinol (17) with geranyl bromide and prenyl bromide to 
form 1-geranylphloroglucinol [2-(3,7-dimethylocta-2,6-dienyl)benzene-1,3,5-triol] (49) and 1-
prenylphloroglucinol [2-(3-methylbut-2-enyl)benzene-1,3,5-triol] (50), respectively.  This was 
performed by two methods, the first being a Friedel-Craft-type alkylation where ZnCl2 was 
used as the Lewis acid.  The second method involved a nucleophillic substitution reaction 
where the base, K2CO3, abstracts a proton from one of the phloroglucinol hydroxyl groups 
resulting in the formation of a phenoxide ion.  The phenoxide ion can then be prenylated in the 
ortho position by alkylating with prenyl or geranyl bromide.  This is achieved as the 
phenoxide anion acts as a nucleophile and attacks the alkyl halide at the electrophilic carbon.  
The bromide ion, being a good leaving group, is simultaneously released and the nucleophilic 
substitution reaction is complete.  The major disadvantage associated with this type of C-
alkylation is the possibility that a number of products can form.  These products arise from the 
various resonance structures available for the phenoxide ion, which allows alkylation to occur 
at the ortho and para positions as well as on the phenoxide oxygen.  Unfortunately both of 






(49) (50)  
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On reviewing the literature, an article was found that reported that prenylation of  
acetophenone precursors was more successful than prenylation of the phloroglucinols.29  For 
this reason we changed our approach, and first prepared the acylated phloroglucinol 
derivatives before attempting the direct C-alkylation. 
 
A Friedel-Craft type alkylation was attempted where 24 (1 eq.) was reacted with geranyl 
bromide (1.5 eq.) in the presence of a Lewis acid, AlCl 3.  A second reaction was also carried 
out where prenyl bromide was used as the alkylating agent instead of geranyl bromide.  Both 
these reactions were unsuccessful. 
 
Qi and Porco30 reported a prenylation of 24 via a nucleophilic substitution reaction.  In this 
reaction a base, KOH, abstracts a proton from one of the phloroglucinol hydroxyl groups.  A 
phenoxide ion is formed which acts as a nucleophile and attacks the alkyl halide. As 
previously mentioned, the major disadvantage associated with this type of C-alkylation is the 
possibility that a number of products can form.  This was evident in the research by Qi and 
Porco, who obtained a bisprenylated product in 45% yield.30  This approach, utilizing an 
aqueous KOH solution, was attempted for the alkylation step in the synthesis of analogues 4 
and 5 using geranyl bromide and prenyl bromide, respectiv ly.  Unfortunately, analysis by 
NMR spectroscopy showed that the desired mono-alkylated products were not obtained. 
 
An alternative method of direct C-alkyltion by nucleophillic substitution resulted in promising 
yields of 74% and 78% by Lee t al.20 and Huang et al.19, respectively.  In an attempt to 
reproduce these results, commercially available 2,4,6-trihydroxy acetophenone (19) was 
refluxed with geranyl bromide in the presence of anhydrous potassium carbonate in dry 
acetone.  Although analogue 4 was obtained, our yield of only 23% was much lower than 
those previously obtained by Lee t al.20 and Huang et al.19  The same reaction conditions 
were used to alkylate 24, which resulted in a poor yield of 6% for the bioactive compound 2.  
The TLC gave evidence that many other products were produced during the reaction, one of 
which was isolated and found to be the O-alkylated product.  This product was obtained in a 
greater yield (12%) than the desired compound and thus indicated that the reaction conditions 
favour the O-alkylation over the C-alkylation. 
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An attempt to alkylate 24 and 2,4,6-trihydroxyacetophenone (19) with prenyl bromide (instead 
of geranyl bromide) via this method was unsuccessful in the production of 3, however, 5 was 
obtained in a yield of 32%. 
 
Alkylation of the acylphloroglucinol derivatives was lso accomplished by a similar approach 
where a stonger base, sodium hydride, was used in place of potassium carbonate.  The 
reactions were performed in dry dioxane with either prenyl or geranyl bromide as the 
alkylating agent.  Following the reaction conditions expressed by Kuhnke and Bohlmann16 and 
Bharate et al.31 resulted in the successful production of our bioactive compound 2 (17%) as 
well as all seven analogues 3 - 9 (19%; 29%; 29%; 17%; 13%; 15% and 10% yields, 
respectively). 
 
The low yields are most likely attributed to the occurrence of polyalkylation as well as 
alkylation of the phenoxide oxygen.  The fact that our acylphloroglucinol derivatives contain 
three hydroxyl moieties increases the degree of by-products or competing reactions that may 
occur.  The poor yields obtained suggest that the reaction conditions need to be evaluated and 
optimized.  Unfortunately, due to time constraints, the optimization of the reaction conditions 
was not carried out. 
 
4.2.3.1 Structural Elucidation of Compounds 2-9 
 
The alkylated acylphloroglucinol derivatives 2 - 9 were fully characterized by NMR (1H, 13C, 
DEPT90, DEPT135, COSY, HSQC and HMBC) spectroscopy, ultraviolet spectroscopy (UV), 
infra-red spectroscopy (IR) and electrospray mass spectrometry (ESIMS). 
 
The NMR data for the acylated phloroglucinol fragment (24) for 2 (Plates 8.1 - 8.2) and 
3 (Plates 9.1 – 9.2) was observed to be the same as described in Section 4.2.2.1 (Table 4.2). 
Similarly, the inclusion of the acylated fragments in 6 and 7, and 8 and 9 are discussed in 
greater depth as compounds 25 and 26 (Table 4.3 in section 4.2.2.1), respectively. The major 
difference is evident in the δH 5.81 which integrates for two protons in the acylphloroglucinol 
compounds, but only integrates for one proton in the alkylated compounds.  This shows that 
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The synthesis of analogues 4 and 5 involved the alkylation of commercially available 
phloroacetophenone (19).  The phloroacetophenone (19) fragment is recognized in the NMR 
spectra obtained for analogues 4 (Plates 10.1 and 10.2) and 5 (Plates 11.1 and 11.2).  The 13C 
NMR spectrum shows a set of three quartenary signals i  the region characteristic of phenolic 
carbons thus denoting the presence of a phloroglucinol moiety.  Another quaternary carbon 
resonating further downfield at δC 204.8 is indicative of a carbonyl functional group.   
 
The 1H NMR spectrum revealed sharp singlet (δH 5.90, 1H), which when compared to 
compounds 24, 25 and 26 allowed us to assign it as the methine group at the unsubstituted 
position of the phloroglucinol ring.  The fact that this signal, which correlates to the carbon 
resonating at δC 95.0, only integrates for one proton indicates that e phloroglucinol core of 
the alkylated compound is di-substituted.  The methyl group of phloroacetophenone appeared 
at δH 2.60 (3H, s) and correlated to the carbon resonating at δC 33.0 in the HSQC.  It was also 



























































Prenylation of 24 – 26 and phloroacetophenone (19) resulted in analogues 3, 7 (Plates 12.1 
and 12.2), 9 (Plates 13.1 and 13.2) and 5, respectively (Table 4.4 and Table 4.5).  The 
1H NMR data of 3 (Plate 9.1) revealed a doublet at δH 3.24 (2H, J = 7.2 Hz), which suggested 
that C-alkylation had occurred.  If O-alkylation had occurred, we would expect the signal to 
resonate further downfield at approx. δH 4. This was further confirmed by the signal at δH 
5.89, which integrated for one proton, indicating that the phloroglucinol ring was di-
substituted and no longer monosubstituted as in the acyl phloroglucinol derivatives where the 
signal with similar chemical shift integrated for two protons.  The proton resonating at δH 3.24 
coupled to one of the phenolic carbons (δC 164.4) of the phloroglucinol ring (HMBC 
experimental data). This implied that the signal at δH 3.24 may be assigned to the protons on 
the carbon of the prenyl side chain that is situated closest to the phenolic ring.  The HMBC 
showed further correlation of this proton signal (δH 3.24) to two quarternary carbons (δC 108.5 
and δC 131.8) and a methine carbon (δC 124.6).  The proton of the latter was observed as a 
triplet (δH 5.24, 1H, J = 7.2 Hz), which correlates to δC 124.6 in the 13C NMR spectrum 
(Plate 9.2).  This denotes the presence of an alkene.  
 
 Two methyl group protons appearing in the 1H NMR spectrum at δH 1.66 and δH 1.76, (3H, s) 
correlated to carbons resonating at δC 26.1 and δC 18.0.  The HMBC experiment revealed long 
range 13C-1H coupling between the two methyl groups and both methyl protons coupled to a 
quaternary carbon (δC 131.8) and the assigned methine moiety (C-2”).  Combining all the 
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information described above we concluded that a prenyl side chain had been introduced via
direct C-alkylation.   
 
A comparison between the data obtained for 3 and the data obtained for 7, 9 and 5 showed that 
the prenyl side chain had been successfully introduce  to each of our acylphloroglucinol 
derivatives via direct C-alkylation.  Our conclusions were further confirmed by comparing our 
acquired experimental data with that of prenylated compounds reported in literature.18, 32 
 
Table 4.4 NMR data of compound 3
Carbon C 
H                    
(Int., Mult., J/Hz) HMBC Correlation 
1 105.6     
2 164.4     
3 108.5     
4 163.4     
5 95.5 5.89 (1H, s) C-1, C-3, C-4, C-6, C-1' 
6 160.6     
1' 201.2     
2' 143.6     
3', 7' 128.7 7.53 (2H, d, J = 7.0) C-1', C-4', C-5', C-6' 
4', 6' 129.4 7.36 (2H, t, J = 7.3) C-2', C-3', C-4' 
5' 130.8 7.42 (1H, t, J= 7.3) C-4', C-6' 
1" 22.4 3.24 (2H, d, J = 7.2) C-2, C-3, C-4, C-2", C-3",  
2" 124.6 5.24 (1H, t, J = 7.2)   
3" 131.8     
4" 18.0 1.76 (3H, s) C-2", C-3", C-5" 




Table 4.5. NMR data acquired for analogues 5, 7 and 9 
 
  Compound 5 Compound 7 Compound 9 
Carbon C 
H                  
(Int., Mult., J/Hz) 
HMBC 
Correlation C 
H                    
(Int., Mult., J/Hz) 
HMBC 
Correlation C 
H                    
(Int., Mult., J/Hz) 
HMBC 
Correlation 
1 204.8     211.7     211.9     
2 33.0 2.60 (3H, s) C-1, C-1' 46.8 3.88 (1H, sextet, J = 6.8)   40.1 4.00 (1H, heptet, J = 6.7)   
3       28.4 
1.35 (1H, m,)           
1.80 (1H, m,)   
C-1, C-2,    
C-4, C-5 
19.9 1.12 (6H,d, J =  6.9) 
C-1, C-2,   
C-4 
4       12.5 0.89 (3H, t,J = 7.4) C-2, C-3 19.9 1.12 (6H,d, J = 6.9) 
C-1, C-2,   
C-3 
5       17.4 1.10 (3H, d, J = 6.8) 
C-1, C-2,  
C-3 
      
1' 105.7     105.4     104.7     
2' 164.9     165.4     165.5     
3' 108.1     108.3     108.3     
4' 164.0     163.5     163.6     
5' 95.0 5.90 (1H, s) 
C-1', C-3', 
C-4', C-6' 
95.2 5.88 (1H, s) 
C-1', C-3', 
C-4', C-6' 
95.1 5.89 (1H, s)   
6' 162.0     161.2     161.2     
1" 22.3 3.17 (2H, d, J = 7.2) 
C-2', C-3', 
C-2", C-3" 
22.4 3.17 (2H, d, J = 7.0) 
C-2', C-3',   
C-2", C-3", 
22.3 3.17 (2H, d, J = 7.0) C-2" 
2" 124.7 5.17 (1H, t, J = 7.2)   124.7 5.17 (1H, t, J = 7.0)   124.8 5.17 (1H, t, J = 7.0)   
3" 131.3     131.3     131.2     
4"* 17.9 1.73 (3H, s) 
C-2", C-3", 
C-5" 
18.0 1.73 (3H, s) 
C-2", C-3",  
C-5" 
18.0 1.73 (3H, s) 
C-2", C-3", 
C-5" 
5"* 26.1 1.63 (3H, s) 
C-2", C-3", 
C-4" 
26.1 1.64 (3H, s) 
C-2", C-3",  
C-4" 
26.1 1.64 (3H, s) C-3", C-4" 
* Assignments of 4” and 5” are interchangeable 
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Alkylation of 24 – 26 and phloroacetophenone (19) with geranyl bromide resulted in the 
bioactive compound 2 and analogues 6 (Plates 14.1 and 14.2), 8 (Plates 15.1 and 15.2) and 
4, respectively (Table 4.6 and Table 4.7).  The NMR data acquired showed some 
similarities when compared to the data obtained for the prenylated compounds.  These 
similarities included the appearance of a singlet at δH 5.90 (1H), a doublet at δH 3.18 (2H, 
J = 7.2 Hz) coupling to a triplet at δH 5.17 (1H, J = 7.0 Hz).  As mentioned earlier, these 
signals suggest that C-alkylation has occurred on the phloroglucinol ring with δH 3.18 being 
the first carbon (C-1”) in the alkyl side chain, whic  in turn is attached to the methine 



































































The 1H NMR spectrum also revealed two multiplets at δH 1.93 and δH 2.03 (correlating to 
δC 41.1 and δC 27.9, respectively), which integrated for two protons each.  The former 
proton showed long-range 13C-1H coupling to C-2” and to a quaternary carbon (δC 134.9), a 
methylene carbon (δC 27.9) and a methyl group (δC 16.3), whilst the latter is also coupled to 
the quaternary carbon at δC 134.9, as well as to a methylene carbon (δH 41.1) and a methine 
carbon (δC 125.7).  The HMBC correlations therefore imply that C-2” is attached to a 
quaternary carbon (C-3”) with a methyl substituent (C-9”).  C-3” is also attached to the 
methylene group (C-4”) that appears at δH 1.93 in the 1H NMR spectrum.  The fact that 
signals δH 1.93 (C-4”) and δH 2.02 couple to each other indicates that they are adjacent to 
one another.  Thus the signal at δH 2.02 is assigned to be C-5”.  The methine carbon 
(δC 125.7) correlates to the triplet resonating at δH 5.04 (1H) in the 1H NMR spectrum 
(C-6”).  
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 The only signals unaccounted for thus far in the 1H NMR spectrum are the two singlets 
appearing at δH 1.61 and δH 1.55 and integrating for three protons each, thus indicating the 
presence of two methyl groups.  The HMBC data showed long-range 13C-1H coupling 
between the two methyl groups as well as to C-6” and  quaternary carbon resonating at δC 
132.1.  The quaternary carbon was assigned to C-7”, whilst the methyl groups were 
assigned as C-8” and C-10” (these two signals are interchangeable).   
 
The information described above as well as the comparison of our data to that reported in 
literature17, led us to conclude that a geranyl substituent had been successfully introduced 

































Table 4.6 NMR data of compound 2. 
Carbon C 
H                        
(Int., Mult., J/Hz) HMBC Correlation 
1 105.6     
2 164.4     
3 108.5     
4 163.5     
5 95.5 5.88 (1H, s) C-1, C-3, C-4, C-6, C-1'  
6 160.7     
1' 201.2     
2' 143.7     
3', 7' 129.3 7.50 (2H, d, J = 7.0) C-1', C-4', C-6' 
4', 6' 128.7 7.35 (2H, d, J = 7.3) C-2', C-3', C-7' 
5' 131.8 7.42 (1H, t, J = 7.3) C-4', C-6' 
1 " 22.4 3.24 (2H, d, J = 7.0) C-2, C-3, C-4, C-2", C-3" 
2" 124.6 5.23 (1H, t, J = 7.0)   
3" 135.1     
4" 41.1 1.96 (2H, m) C-2", C-3", C-5", C-9" 
5" 27.9 2.05 (2H, m) C-4", C-6", C-7" 
6" 125.7 5.06 (1H, t, J = 7.0)   
7" 132.1     
8"* 26.0 1.61 (3H, s) C-6", C-7", C-10" 
9" 16.4 1.76 (3H, s) C-2", C-3", C-4" 
10"* 17.9 1.56 (3H, s) C-6", C-7", C-8" 
 * Assignments are interchangeable 
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Table 4.7 NMR data acquired for analogues 4, 6 and 8 
 
  Compound 4 Compound 6 Compound 8 
Carbon C H                 (Int., Mult., J/Hz) 
HMBC 
Correlation C 
H                    
(Int., Mult., J/Hz) 
HMBC 
Correlation C 
H                     
(Int., Mult., J/Hz) 
HMBC 
Correlation 
1 204.7           211.9     
2 33.0 2.60 (3H, s) C-1, C-1'  46.8 
3.88 (1H, sextet,         
J = 6.7) 
  40.0 
4.00 (1H, heptet,         
J = 6.6) 
C-1, C-3,  
C-4, 
3       28.3 
1.36 (1H, m)         
1.80 (1H, m)   
  19.9 1.12 (6H,d, J = 6.9) 
C-1, C-2,  
C-4 
4       12.5 0.89 (3H, t, J = 7.4) C-2, C-3 19.9 1.12 (6H,d, J = 6.9) 
C-1, C-2,  
C-4 
5       17.4 1.10 (3H, d, J = 6.7) 
C-1, C-2,  
C-3 
      
1' 105.7           104.7     
2' 164.9     165.3     165.4     
3' 108.1      106.7     108.4     
4' 164.0      163.4     163.5     
5' 95.0 5.90 (1H, s) 
C-1', C-3', 
C-4', C-6' 
95.3 5.90 (1H, s)   95.1 5.89 (1H, s) 
C-1', C-3', 
C-4', C-6' 
6' 161.9     163.4      161.1     
1" 22.2 
3.18 (2H, d,        
J = 7.2) 
C-3', C-4',  
C-2", C-3" 




5.17 (1H, t,         
J = 7.0) 
  124.8 5.17 (1H, t, J = 7.4)   124.8 5.17 (1H, t, J = 7.0)   
3" 134.9     134.9     134.8     
4" 41.1 1.93 (2H, m)   41.0 1.93 (2H, m)   41.0 1.93 (2H, m) 
C-3", C-5", 
C-9" 





Table 4.7 NMR data acquired for analogues 4, 6 and 8 continued. 
 
  Compound 4 Compound 6 Compound 8 
Carbon C H                 (Int., Mult., J/Hz) 
HMBC 
Correlation C 
H                    
(Int., Mult., J/Hz) 
HMBC 
Correlation C 
H                     




5.05 (1H, t, J = 
7.0) 
  125.7 5.03 (1H, t, J = 7.4)   125.6 5.04 (1H, t, J = 7.0)   
7" 132.1     132.1     132.1     
8"* 25.9 1.61 (3H, s) 
C-6", C-7", 
C-10" 
26.0 1.60 (3H, s) 
C-6", C-7", 
C-10" 
26.0 1.60 (3H, s) 
C-6", C-7", 
C-10" 
9" 16.3 1.73 (3H, s) 
C-2", C-3", 
C-4"  
16.3 1.73 (3H, s) 
C-2", C-3", 
C-4" 
16.3 1.73 (3H, s) 
C-2", C-4", 
C-3" 
10"* 17.8 1.55 (3H, s) 
C-6", C-7", 
C-8" 
17.9 1.54 (3H, s) 
C-6", C-7", 
C-8" 
17.8 1.54 (3H, s) 
C-6", C-7", 
C-8" 




Biological activity and toxicity testing is currently being carried out on our battery of eight 
synthetic compounds.  Therefore future work would involve the evaluation of the results 
obtained in order to draw some conclusions on the sructure-activity relationships of the 
various groups present in our molecules.  If signifcant biological activity is exhibited by 
one or more of our synthesized analogues, future work uld need to include an attempt to 
increase the yields of the compounds of interest.  This may be achieved by optimizing the 
reaction conditions of the direct C-alkylation method by which the analogues were 
produced or investigation into alternative routes may be considered.  Although the 
carcinogenic nature of the MOM protecting group needs to be taken into account, as well 
as the fact that it is no longer commercially available, it may be interesting to synthesize 
MOMCl and hence attempt the C-prenylation via O-alkylation followed by the Claisen 
rearrangement as good yields are expressed by Tan et l.21  The MOM protecting group is 
also known to be a good ortho directing group.  Another potential method involves 





4.4.1 Standard Experimental Techniques 
 
The chromatographical techniques as well as instrumentation utilized in the synthetic 
section of the research, are the same as that reported in Chapter 3 (Section 3.4.1).  IR data 
is only reported between 1500 and 3500 cm-1. 
 
All anhydrous reactions were performed under an inert itrogen atmosphere with solvents 
previously dried using an Innovative Technology Pure Solv MD-7 solvent purification 
system (THF and DCM) or by drying the solvent over an appropriate drying agent 
(Acetone and DMF: molecular sieves, dioxane: Na) followed by distillation under nitrogen 
The Pure Solv MD-7 solvent purification system is composed of steel canisters under a 
positive N2 pressure and uses a drying agent comparable to molecular sieves.  This 
technique does not require any heat and thus no peroxid s are formed.  Reagents such as 
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phloroglucinol  (17) and phloroacetophenone (19) were dried in an oven at 120 °C for 
24 hours and thereafter stored in a dessicator prioto use.  The glassware required for the 
reactions were also dried in an oven and flushed with nitrogen prior to use.  All alkylating 
agents were added with a syringe via a septum. 
 
The reactions were monitored using silica coated aluminium or glass TLC plates.  Unless 
specified to the contrary, the TLC plates were eluted with Hex:EtOAC (2:1) and viewed 
under UV light before being sprayed with anisaldehyde stain reagent and heated with a 
heat gun. 
 
Unless stated otherwise, the standard work-up procedure involved: quenching the reaction 
with 1 M HCl or dist. H2O, extracting the reaction mixture with DCM (3 x 20mL) or 
EtOAc (3 x 30 mL), drying the organic extract over MgSO4 and concentrating in vacuo.  
Purification was then carried out on either a 2 mm or 4 mm chromatotron plate.  Pure 
compounds were analysed by NMR spectroscopy in deuterated chloroform or methanol. 
 
4.4.2 Synthetic Procedures 
 






















(19) (41)  
 
K2CO3 (2.47 g, 17.9 mmol) was added to a solution of DMF (20 mL) and 
phloroacetophenone (19) (1.01 g, 6.01 mmol).  The reaction mixture was allowed to stir for 
a time period of 15 minutes before benzyl chloride (1.0 mL, 12.2 mmol) dissolved in DMF 
(3 mL) was added.  The reaction mixture was refluxed for 2 h after which TLC showed 
that the reaction had gone to completion.  The reaction was quenched with 1 M HCl 
(15 mL) and extracted with DCM.  The organic layers were combined, washed with ice 
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water (6 x 30 mL), dried and concentrated in vacuo.  Column chromatography (silica 
height: 14 cm, loaded as a slurry) was used to remov  the polar compound observed on the 
baseline of the TLC plate (Hex:EtOAc 9:1). Further purification of the product was 
performed on a chromatotron.  The organic fraction was loaded onto a 4 mm chromatotron 
plate and eluted with Hex:EtOAc (9:1).  The bisbenzylated product 41 (1.46 g, 70%) was 
obtained as creamy-yellow needle-like amorphous solid.    Melting point: 93-95 °C 
(MeOH); UV(MeOH) λmax (log ε): 287 (4.94) nm; 1H NMR (CDCl3, 400 MHz): δH 2.55 
(3H, s, H-2), 5.06 (4H, s, H-2”), 6.10 (1H, d, J = 2.3 Hz, H-5’), 6.16 (1H, d, J = 2.3 Hz, 
H-3’), 7.40 (10H, m, Ar), 13.99 (1H, s, OH);  13C NMR (CDCl3, 400 MHz):  δC 33.3 (C-2), 
70.3 (C-2”), 71.1 (C-2”), 92.4 (C-3’), 94.8 (C-5’), 106.4 (C-1’), 127.6 – 128.7 (Ar-CH), 
135.6 (Ar-C), 135.9 (Ar-C), 162.0 (C-6’), 165.1 (C-4’), 167.6 (C-2’), 203.1 (C-1);  ESIMS:  
m/z 371.1262 [M+Na]+ (calculated for C22H20O4Na, 371.1259).  
 
A by-product was also isolated from the fractions collected in a yield of 28% and was 
found to be the tribenzylated product (42).  1H NMR (CDCl3, 400 MHz): δH 2.49 (3H, s, 
H-2), 5.01 (2H, s, H-2”), 5.06 (4H, s, H-1”), 6.26 (1H, s, H-3’, H-5’), 7.38 (15H, m, Ar);  
13C NMR (CDCl3, 400 MHz):  δC 32.6 (C-2), 70.2 (C-2”), 70.6 (C-1”), 93.6 (C-3’, C-5’), 
115.2 (C-1’), 128.6 – 128.7 (Ar-CH), 136.4 (Ar-C), 157.1 (C-2’, C-6’), 161.1 (C-4’), 201.3 
(C-1).   
 


















Phloroglucinol (17) (602 mg, 4.77 mmol) and K2CO3 (3.29 g, 28.83 mmol) were dissolved 
in DMF (20 mL) and allowed to stir for 20 min before benzyl chloride (1.76 mL, 
21.4 mmol) was added.  The reaction mixture was heated to 80 °C.  The reaction was 
quenched after 9 h with 1 M HCl (15 mL) and extracted with DCM.  The organic fractions 
were combined and washed with ice water (6 x 30 mL) before being dried and 
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concentrated in vacuo.  Column chromatography (diameter: 3 cm, silica heig t: 15 cm, 
loaded as a slurry) yielded the trisbenzylated phloroglucinol 48 (869 mg, 46%). 
 IR (KBr) νmax:  3028, 2868, 1592 cm-1; 1H NMR (CDCl3, 400 MHz): δH 5.01 (6H, s, 
H-1”), 6.27 (3H, s, H-2, H-4, H-6), 7.38 (15H, m, Ar-H);  13C NMR (CDCl3, 400 MHz):  
70.2 (C-1’), 95.0 (C-2, C-4, C-6), 127.6 – 128.6 (Ar-CH), 136.9 (Ar-C), 160.7 (C-1, C-3, 
C-5). 
 


















(19) (43)  
Method 1 
 
Phloroacetophenone (19) (100 mg, 0.56 mmol) and NaH (90 mg, 3.75 mmol) were 
dissolved in THF (15 mL) and allowed to stir at 0 °C for 1 h before MeI (0.17 mL, 2.68 
mmol) was added.  The reaction was quenched with dist. H2O (5 mL) after 18 h when no 
more starting material was present.  The reaction products were extracted with DCM 
(3 x 15 mL); the organic fractions were combined andried before being concentrated in 
vacuo.  Purification was performed on a 2 mm chromatotron plate, which yielded 
dimethylated phloroacetophenone 43 (2 mg, 2%).  IR (KBr) νmax:  2940, 1584 cm-1;  
1H NMR (CDCl3, 400 MHz): δH 2.61 (3H, s H-2), 3.83 (6H, 2 x s, H-1”), 5.92 (1H, d, 
J = 2.4 Hz, H-5’), 6.06 (1H, d, J = 2.4 Hz, H-3’), 14.0 (1H, s, OH);  13C NMR (CDCl3, 400 
MHz):  32.9 (C-2), 55.6 (C-1”), 90.8 (C-5’), 93.6 (C-3’), 106.1 (C-1’), 162.9 (C-6’), 166.1 




Phloroacetophenone (19) (202 mg, 1.20 mmol) and NaH (180 mg, 7.50 mmol) were 
dissolved in THF (15 mL) and allowed to stir for 1 h before MeI (0.33 ml, 5.35 mmol) was 
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added.  The reaction mixture was heated until gently ref uxing (70 °C).  The reaction was 
quenched after 4 h with dist. H2O (15 mL) and extracted with DCM.  The organic fractions 
were combined, dried and concentrated.  The residue was purified on a 2 mm chromatotron 
plate, eluted with Hex:EtOAc (9:1).  Dimethylated phloroacetophenone 43 was not 




Phloroacetophenone (19) (306 mg, 1.82 mmol) and K2CO3 (1.23 g, 5.92 mmol) were 
dissolved in acetone (20 mL) and allowed to stir under N2 for 30 min. before MeI was 
added.  The reaction mixture was heated until gently ref uxing (60 °C).  After refluxing for 
6 h TLC showed that no starting material remained an thus the reaction was quenched 
with dist. H2O (10 mL) and extracted with EtOAc.  The organic layers were combined, 
dried and concentrated in vacuo.  Purification was performed on a 2 mm chromatotron 
plate, which yielded dimethylated phloroacetophenon 43 was obtained in a low yield of 
12.6% (45 mg). 
 
































Anhydrous K2CO3 (163 mg, 1.18 mmol) was added to bisbenzylated 
phloroacetophenone 41 (198 mg, 0.568 mmol) dissolved in acetone (8 mL) and the 
resulting reaction mixture was allowed to stir for 15 minutes before prenyl bromide 
(87 mg, 0.58 mmol), dissolved in acetone (3 mL), was added.  The prenyl bromide addition 
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was carried out slowly.  The reaction mixture was heated until it was gently refluxing 
(58 °C). The progress of the reaction was monitored by TLC.  Although the reaction had 
not yet gone to completion, it was quenched with water (10 mL) after refluxing for a time 
period of 100 h.  The reaction mixture was then partitioned with DCM and water.  The 
organic layer was dried and the remaining solvent was removed in vacuo.  The sample 
underwent purification on a 2 mm chromatotron plate (Hex:EtOAc 9:1) yielding the 
desired O-prenylated product (44)( 81 mg, 34%).   
1H NMR (CDCl3, 400 MHz): δH 1.73 (3H, s, H-5”), 1.79 (3H, s, H-4”), 2.51 (3H, s, H-2), 
4.51 (2H, d, J = 7.0 Hz, H-1”), 5.05 (4H, s, H-6”), 5.44 (1H, t, J = 7.0 Hz, H-2”), 6.25 (1H, 
s, H-5’) 6.27 (1H, s, H-3’), 7.40 (10H, m, Ar-H);  13C NMR (CDCl3, 400 MHz):  18.0 
(C-5”), 25.7 (C-4”), 32.6 (C-2), 65.5 (C-1”), 70.2 (C-6”), 93.0 (C-5’), 93.2 (C-3’), 119.3 
(C-2”), 126.9-128.5 (C-Ar), 136.4, 137.5, 160.9, 157.3, 156.9, 201.2 (C-1);  ESIMS:  




Bisbenzylated phloroacetophenone 41 (350 mg, 1.01 mmol) was dissolved in DMF 
(10 mL) and placed in a 3-neck round bottom flask equipped with a stirrer bar, condenser, 
N2 line and a septum.  Anhydrous K2CO3 (280 mg, 2.03 mmol) was added to the vessel and 
the resulting reaction mixture was allowed to stir for 15 minutes before prenyl bromide 
(152 mg, 1.02 mmol) dissolved in DMF (3ml) was added.  The prenyl bromide addition 
was carried out slowly and the resulting reaction mixture was heated to 80 °C. The 
progress of the reaction was monitored by TLC which showed that after 17 h only starting 
material was present therefore a further equivalent of K2CO3 (143 mg, 1.04 mmol) and 
2 equivalents of prenyl bromide (310 mg, 2.08 mmol) was added and the temperature 
increased to 100 °C.  Proton NMR spectra of the reaction mixture after 24 and 40 hours 
showed starting material but no O-alkylated product 44.  A small amount of dibenzo-18-
crown-6 (45) was added.  Although the reaction had not yet gone t  completion it was 
quenched with 1 M HCl (10 mL) after 4.5 days.  The reaction mixture was then extracted 
with DCM and the aqueous layer discarded.  The combined DCM layers were washed with 
ice water (5 x 40 mL), brine (3 x 30 mL) and dried over MgSO4.  The remaining solvent 
was removed in vacuo.  The sample underwent purification on a chromatotron (4 mm 
plate, Hex:EtOAc 9:1).  The fractions collected were spotted on TLC (Hex:EtOAc 2:1).  
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The TLC did not show a good separation, thus the desired product 44 could not be isolated 




Bisbenzylated phloroacetophenone 41 (100 mg, 0.29 mmol) dissolved in acetone (6 mL) 
was placed in a 2-necked reaction vessel equipped with a stirrer bar, thermometer, 
condenser and N2 line.  Anhydrous K2CO3 (119 mg, 0.86 mmol) and dibenzo-18-crown-6 
(45) (106 mg, 0.29 mmol) was added and the reaction mixture was allowed to stir for 
30 minutes before prenyl bromide (90 mg, 0.60 mmol) dissolved in acetone (2 mL) and 
copper iodide (CuI) (4 mg, 0.023 mmol) was added.  The reaction mixture was heated until 
it was gently refluxing (59 °C). TLC showed that after 5 h the reaction had gone to 
completion. The reaction was quenched with dist. H2O (5 mL).  The reaction products 
were extracted with DCM (3 x 15 mL), the organic fractions were combined and the 
aqueous layer discarded.  The organic layer was dried and the remaining solvent was 
removed.  The sample underwent purification on a chromatotron (2 mm plate, 




Sodium hydride (NaH) (110 mg, 4.58 mmol) was placed into a 3-necked round-bottom 
flask fitted with a stirrer bar, thermometer, condes r N2 line and a septum.  Bisbenzylated 
phloroacetophenone 41 (502 mg, 1.44 mmol) was dissolved in THF (20 mL) and allowed 
to stir for 1.5 hours before adding prenyl bromide (430 mg, 2.89 mmol) dissolved in THF 
(2 mL).  The reaction mixture was heated to 60 °C.  After 4.5 h, TLC showed that the 
desired prenylated product 44 was present.  The reaction was quenched with dist. H2O 
(10 mL) and extracted with DCM (3 x 15 mL). The organic layer was dried and 
concentrated.  The aqueous layer was discarded.   The organic fraction was purified on a 
chromatotron, where the fraction was dissolved in DCM, loaded onto a 4 mm 
chromatotron plate and eluted with Hex:EtOAc (9:1).  1-[2,4-bisbenzyloxy-6-(3-






NaH (23 mg, 0.96 mmol) was placed intro a 3-necked round bottom flask and dissolved in 
DMF (15 mL added to vessel via a canula).  Bisbenzylated phloroacetophenone 41 (99 mg, 
0.28 mmol) was added and the reaction mixture allowed to stir for a time period of 1.5 h 
before prenyl bromide (88 mg, 0.59 mmol) dissolved in DMF (2 mL) was added.  The 
reaction mixture was the heated to 80 °C.  TLC showed that alkylation had taken place 
after 4 h.  The reaction was quenched after 4.5 h wit  1 M HCl (10 mL) and extracted with 
DCM.  The aqueous layer was discarded and the organic fraction was washed with ice 
water (6 x 30 mL), dried and concentrated.  Column chromatography (10 mL syringe 
plugged with cotton wool and filled to the 8 ml mark with silica gel, Hex:EtoAc 9:1) was 
used to remove the polar compound observed on the bas line of the TLC plate. Further 
purification of the product was performed on a chromatotron (2 mm plate, 
Hex:EtOAc 9:1).   1-[2,4-Bisbenzyloxy-6-(3-methylbut-2-enyloxy)phenyl]ethanone 44 
was obtained in 45% yield (53 mg). 
 


















The O-prenylated bisbenzylated phloroacetophenone 44 (146 mg, 0.35 mmol) was 
dissolved in N,N-dimethylaniline (3 mL) and heated to 200 °C.  The reaction was 
monitored by TLC, which showed that the reaction had gone to completion after a time 
period of 3 h, thus the reaction was quenched with 1 M HCl (10 mL).  The reaction 
products were extracted with EtOAc and the organic fra tions combined.  The organic 
fraction was then washed with 1 M HCl (2 x 15 mL), dist. H2O (2 x 15 mL) and brine (2 x 
15 mL) before being dried and concentrated on a rottory evaporator.  The remaining 
residue was purified on a 2 mm chromatotron plate (H x:EtOAc 9:1).  NMR spectroscopy 
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showed that 50:50 mixture of the desired product 46 and (1-[4,6-bisbenzyloxy-3-(1,1-
dimethylallyl)-2-hydroxyphenyl]ethanone 47 was obtained in 57% yield (83 mg). 
 














K2CO3 (130 mg, 0.94 mmol) was added to a solution of acetone (6 mL) and 
phloroacetophenone (19) (110 mg, 0.654 mmol).  The mixture was allowed to s ir for 
10 minutes before geranyl bromide (0.11 ml, 1.00 mmol) dissolved in acetone (2 mL) was 
added slowly and refluxed (58 °C) for 4 h.  Although the reaction had not gone to 
completion it was quenched after 4 h by adding 1 M HCl (10 mL).  The reaction products 
were extracted with DCM.  The organic layers were combined, dried and concentrated.  
The extract was dissolved in DCM and purified on a 2 mm chromatotron plate eluted 
initially with Hex:EtOAc 9:1.  As the separation progressed, the polarity of the solvent 
system was increased as follows:  Hex:EtOAc 3:1, Hex:EtOAc 2:1, and finally washed 
with MeOH.  The desired alkylated product 4 was obtained in a low yield of 11% (17 mg).   
UV(MeOH) λmax (log ε): 287 (4.37) nm;  IR νmax:  3400, 3306, 2917, 1623 cm-1;  1H NMR 
(CD3OD, 400 MHz): δH 1.55 (3H, s, H-10”), 1.61 (3H, s, H-8”), 1.73 (3H, s, H-9”), 1.93 
(2H, m, H-4”), 2.03 (2H, m, H-5”), 2.60 (3H, s, H-2), 3.18 (2H, d, J = 7.3 Hz, H-1”), 5.05 
(1H, t, J = 7.0 Hz, H-6”), 5.17 (1H, t, J = 7.0 Hz, H-2”), 5.90 (1H, s, H-5’);  13C NMR 
(CD3OD, 400 MHz):  δC 16.3 (C-9”), 17.8 (C-10”), 22.2 (C-1”), 25.9 (C-8”), 27.9 (C-5”), 
33.0 (C-2), 41.1 (C-4”), 95.0 (C-5’), 108.1 (C-3’), 105.7 (C-1’),124.8 (C-2”), 125.7 (C-6”), 
132.1 (C-7”), 134.9 (C-3”), 161.9 (C-6’),  164.1 (C-4’), 164.9 (C-2’), 204.7 (C-1);  






K2CO3 (333 mg, 2.41 mmol) was added to a solution of acetone (10 mL) and 
phloroacetophenone (19) (198 mg, 1.18 mmol).  The mixture was allowed to stir for 
10 minutes before geranyl bromide (0.23 ml, 1.19 mmol), dissolved in acetone (2 mL), was 
added slowly and refluxed for 4 h.  The reaction mixture was removed from the heat 
source after 1 day and the acetone evaporated off, leaving a dark brown oil-like residue.  
1 M HCl (20 mL) was added to the residue and extracted with EtOAc (3 x 50 mL).  The 
organic layers were combined, dried and concentrated in vacuo.  The organic layer was 
dissolved in DCM and purified on a 4 mm chromatotron plate eluted initially with 
Hex:EtOAc (7:1).  As the separation progressed the polarity of the solvent system was 
increased as follows:  Hex:EtOAc (3:1), Hex:EtOAc (1:1), Hex:EtOAc (1:2), 100% EtOAc  
and finally washed with MeOH.    3-Geranyl-2,4,6-trihydroxyacetophenone 4 was obtained 




Phloroacetophenone (19) (203 mg, 1.21 mmol) was dissolved in an aq. KOH soluti n 
[KOH (98 mg, 1.75 mmol) dissolved in 3 mL dist. H2O] and placed in an ice-bath (0 °C).  
Geranyl bromide (0.23 mL, 1.19 mmol) was added dropwise over a period of 15 minutes.  
The reaction mixture was allowed to stir at 0 °C for 2 h.  The reaction was quenched after 
2 h by pouring the reaction mixture over 1 M HCl (6 mL).  The reaction products were 
extracted with EtOAc; organic fractions were combined, dried and concentrated.  The 
remaining residue was purified on a 4 mm chromatotron plate eluted with: 
Pet. Ether:EtOAC (7:1), Pet. Ether:EtOAc (3:1), Pet. Ether:EtOAc (1:1), 
Pet. Ether:EtOAc (2:1), 100% EtOAc.  The desired product 4 was not obtained and thus 




Phloroacetophenone (19) (200 mg, 1.20 mmol) and NaH (86 mg, 3.59 mmol) was 
dissolved in dioxane (10 mL).  The reaction mixture was allowed to stir for 30 min at room 
temperature (26 °C).  Geranyl bromide (0.34 mL, 1.80 mmol) was added an  the resulting 
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mixture was heated to 60 °C and stirred for a further 4 hr.  The reaction was quenched after 
this time period with dist. H2O (10 mL).  The reaction products were extracted with EtOAc 
(2 x 30 mL); organic fractions were combined, dried and concentrated.   The remaining 
residue was purified on a 2 mm chromatotron plate (eluted with: Hex:EtOAc 9:1, 
Hex:EtOAc 4:1, Hex:EtOAc 2:1, Hex:EtOAc 1:1, 100% EtOAc), which yielded the 
desired product  4 (105 mg, 29 %).  
 













Phloroacetophenone (19) (210 mg, 1.25 mmol) was dissolved in acetone (20 mL) before 
K2CO3 (338 mg, 2.45 mmol) was added and the reaction mixture was allowed to stir for a 
time period of 10 minutes.  Prenyl bromide (0.14 mL, 1.19 mmol) dissolved in acetone 
(3 mL) was added to the reaction vessel and refluxed (60 °C) for 1 day.  The acetone was 
removed in vacuo leaving a brown residue in the flask.  The residue was acidified with 
1 M HCl (20 mL) and extracted with EtOAc (4 x 30 mL).  The organic layers were 
combined, dried and concentrated.  The organic layer was purified on a 4 mm 
chromatotron plate (Hex:EtOAc 7:1, Hex:EtOAc 4:1, Hex:EtOAc 2:1, Hex:EtOAc 1:1, 
Hex:EtOAc 2:1, 100% EtOAc), which yielded 2,4,6-trihydroxy-3-prenylacetophenone (5) 
(89 mg, 34%).   
UV (MeOH) λmax (log ε):  289 (360) nm;  IR νmax:  3527, 3287, 2930, 2453, 1598 cm-1;  
1H NMR (CD3OD, 400 MHz): δH 1.63 (3H, s, H-5”), 1.73 (3H, s, H-4”), 2.60 (3H, s, H-2), 
3.17 (2H, d, J = 7.2 Hz, H-1”), 5.17 (1H, t, J = 7.2 Hz, H-2”), 5.90 (1H, s, H-5’);  
13C NMR (CD3OD, 400 MHz):  δC 17.9 (C-4”), 22.3 (C-1”), 26.1 (C-5”), 33.0 (C-2), 95.0 
(C-5’), 105.7 (C-1’), 108.1 (C-3’), 124.7 (C-2”), 13 .3 (C-3”), 162.0 (C-6’), 164.0 (C-4’), 
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Phloroacetophenone (19) (215 mg, 1.28 mmmol) was dissolved in an Aq. KOH soluti n 
and cooled to 0 °C in an ice bath.  The aq. KOH solution was prepared by dissolving KOH 
(92 mg, 1.64 mmol) in dist. H2O (4 mL).  Prenyl bromide (0.14 mL, 1.19 mmol) was added 
dropwise over a period of 10 minutes.  The reaction mixture was allowed to stir at 0 °C for 
1 h, after which it was poured over 1 M HCl (6 mL).  The reaction products were extracted 
with EtOAc and the combined organic fractions were d ied and solvent removed on a 
rotatory evaporator.  The remaining residue was purified on a 4 mm chromatotron plate 
(Pet. Ether:EtOAc 7:1, Pet. Ether:EtOAc 4:1, Pet. Ether:EtOAc 2:1, Pet. Ether:EtOAc 1:1, 
100% EtOAc).  Fractions were analysed by NMR spectros opy, of which none of the 
spectra illustrated the presence of the desired prenylated phloroacetophenone 5. Thus this 




Phloroacetophenone (19) (200 mg, 1.20 mmol) and NaH (86 mg, 3.59 mmol) was 
dissolved in dioxane (10 mL).  The reaction mixture was allowed to stir for 30 min at room 
temperature (27 °C).  Prenyl bromide (0.21 mL, 1.80 mmol) was added using a syringe and 
the resulting mixture was heated to 60 °C and stirred for a further 4.5 hr.  The reaction was 
quenched after this time period with dist. H2O (10 mL).  The reaction products were 
extracted with EtOAc (2 x 30 mL); organic fractions were combined, dried and 
concentrated.   The remaining residue was purified on a 2 mm chromatotron plate (eluted 
with: Hex:EtOAC 9:1, Hex:EtOAc 4:1, Hex:EtOAc 2:1, Hex:EtOAc 1:1, 100% EtOAc).    



















Phloroglucinol (17) (210 mg, 1.67 mmol) and ZnCl2 (445 mg, 3.27 mmol) were dissolved 
in acetone (20 mL). Geranyl bromide (0.45 mL, 2.38 mmol) was added via a septum using 
a syringe.  The reaction mixture was refluxed at 60 °C.  After a time period of 1 h TLC 
showed that the reaction had gone to completion, thus e reaction was quenched with dist. 
H2O (10 mL) and extracted with DCM.  The organic fractions were dried and concentrated 
in vacuo.  The organic layer was purified on a 2 mm chromatotron plate (Hex:EtOAc 9:1). 




Phloroglucinol (17) (200 mg, 1.59 mmol) and K2CO3 (440 mg, 3.21 mmol) were dissolved 
in acetone (20 mL) and geranyl bromide (0.30 mL, 1.59 mmol) was added via a syringe.  
The reaction mixture was refluxed (60 °C).  The reaction vessel was removed from the heat 
source after 1 day and the acetone was evaporated off.  The remaining residue was 
acidified with 1 M HCl (20 mL) and extracted with EtOAc (4 x 30 mL).  The organic 
fractions were combined and dried.  The concentrated sample was purified on a 4 mm 
chromatotron plate (Hex:EtOAc 7:1, Hex:EtOAc 4:1, Hex:EtOAc 1:1, Hex:EtOAc 1:2 and 
100% EtOAc).  The reaction was considered to be unsuccessful as the desired alkylated 













(17) (50)  
 
Phloroglucinol (17) (205 mg, 1.63 mmol) and ZnCl2 (425 mg, 3.12 mmol) were dissolved 
in acetone (20 mL) and prenyl bromide (360 mg, 2.42 mmol) was added via a septum 
using a syringe.  The reaction mixture was refluxed at 59 °C.  After a time period of 1 h 
TLC showed that the reaction had gone to completion.  Thus the reaction was quenched 
after 1 h with dist. H2O (10 mL) and extracted with DCM.  The organic fractions were 
dried, concentrated and further purified on a 2 mm chromatotron plate (Hex:EtOAc 9:1).  
The desired product 50 was not obtained and therefore the reaction was believed to be 
unsuccessful.  
 
4.4.2.10 Preparation of acyl chlorides 
 
A 2-necked round bottom flask was set-up with a condenser thermometer and stirring bar.  
A pipe was attached to the top of the condenser with a funnel on the other end leading into 
a bath of water.  This was done in order to trap the HCl gas that is released as a by-product 
of the reaction.  Isobutyric acid (10 mL, 110 mmol) r 2-methylbutyric acid (10 mL, 
91.7 mmol) and 1 equivalent of SOCl2 (6.7 mL, 91.7 mmol and 8 mL, 110 mmol, 
respectively) were injected into the vessel and heated until gently refluxing.  The reaction 
mixture was refluxed for 3 h.  Distillation was then carried out in order to separate the acyl 
chloride product from any remaining acid or SOCl2.  Isobutyryl chloride was collected at a 



























Phloroglucinol (17) (205 mg, 1.63 mmol) and ZnCl2 (490 mg, 3.60 mmol) were dissolved 
in DCM (25 mL).  Benzoyl chloride (0.28 mL, 2.38 mmol) was added to the vessel through 
the septum using a syringe.  The reaction mixture was gently refluxed (40 °C) for 2.5 h.  
After this time period the reaction was quenched with dist. H2O (10 mL) and extracted 
with DCM.  The organic layers were dried and the remaining solvent was removed in
vacuo.  The concentrated sample was purified on a 2 mm chromatotron plate, eluted with 
Hex:EtOAc (9:1).  The reaction was unsuccessful as 2,4,6-trihydroxybenzophenone (24) 




Phloroglucinol (17) (200 mg, 1.59 mmol) and AlCl3 (846 mg, 6.34 mmol) were dissolved 
in carbon disulfide (2.5 mL).  Nitrobenzene (1.5 mL) was added over a time period of 
5 min.  The reaction mixture was refluxed (50 °C) for 30 min. before benzoyl chloride 
(0.18 mL, 1.59 mmol) dissolved in nitrobenzene (1 mL) was added to the vessel over 
5 min.  The reaction mixture was refluxed (50 °C) for a further 30 min.  The reaction 
vessel was then removed from the heat source and allowed to stir whilst cooling to room 
temperature.  Dist. H2O (10 mL) and 1 M HCl (5 mL) were added.  The reaction products 
were extracted with EtOAc, the organic layers combined, dried and concentrated.  The 
concentrated sample was purified on a 2 mm chromatotron plate, eluted with progressively 
polar solvent systems: Hex:EtOAc 7:1, Hex:EtOAc 4:1, Hex:EtOAc 2:1, Hex:EtOAc 1:2 
and 100% EtOAc.  2,4,6-Trihydroxy-benzophenone (24) was obtained in 19% yield 
(56 mg). 
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UV(MeOH) λmax (log ε):  306 (4.36) nm;  IR  νmax:  3185, 1597 cm-1;  1H NMR (CD3OD, 
400 MHz): δH 5.81 (2H, s, H-3, H-5), 7.36 (2H, t, J = 7.4 Hz, H-4’, H-6’), 7.45 (1H, t, 
J = 7.45 Hz, H-5’), 7.58 (2H, d, J = 7.4 Hz, H-3’, H-7’);  13C NMR (CD3OD, 400 MHz):  
δC 96.0 (C-3, C-5), 106.1 (C-1), 128.8 (C-4’, C-6’), 129.4 (C-3’, C-7’), 132.2 (C-5’), 143.1 
(C-2’), 164.0 (C-2, C-6), 166.1 (C-4), 200.8 (C-1’);  ESIMS:  m/z 253.0473 [M+Na]+ 




Phloroglucinol (17)  (500 mg 3.97 mmol) was dissolved in DCM (8 mL) and cooled on ice 
(0 °C).  In a separate flask, AlCl3 (1.18 g, 8.86 mmol) was dissolved in DCM (10 mL) and 
cooled on ice (0 °C).  Benzoyl chloride (0.46 mL, 3.97 mmol) was added ropwise with a 
syringe.  The resulting mixture was allowed to stirunder N2 for 2.5 h.  This mixture was 
then added slowly to the phloroglucinol solution.  The reaction mixture was removed from 
the ice bath and set aside.  Once room temperature was reached the reaction mixture was 
stirred for a further 22 h before being quenched by the addition of 1 M HCl (15 mL) and 
dist. H2O (10 mL).  The reaction products were extracted with DCM (2 x 20 mL) followed 
by EtOAc (3 x 30 mL).  All 5 organic fractions were combined, washed with sat. NaHCO3 
(3 x 30 mL), dist. H2O (3 x 30 mL) and brine (3 x 30 mL), dried over MgSO4 and 
concentrated in vacuo.  Purification was carried out on a 2 mm chromatotron plate, eluting 
with Hex:EtoAc 6:1 followed by Hex:EtOAc 1:1.  The d sired product 24 was obtained as 
a pale yellow solid (415 mg, 46%).   
Method 4 
 
Phloroglucinol (17) (830 mg, 6.58 mmol) and AlCl3 (3.41 g, 25.6 mmol) were dissolved in 
nitrobenzene (12 mL) and allowed to stir at room tep rature for 30 min.  Benzoyl 
chloride (0.74 mL, 6.34 mmol) was added with a syringe and the resulting mixture was 
heated to 80 °C for 1.5 h.  During this time the reaction mixture changed colour from pale 
yellow to black.  The reaction mixture was cooled to room temperature before 1 M HCl 
(20 mL) and dist. H2O (15 mL) was added.  The reaction products were extracted with 
EtOAc (4 x 30 mL), organic fractions combined and washed with sat. NaHCO3 
(3 x 30 mL), dist. H2O (3 x 30 mL) and brine (3 x 30 mL).  The EtOAc fraction was then 
dried and concentrated.  Purification was carried out n a 4 mm chromatotron plate 
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(Hex:EtoAc 6:1, Hex:EtOAc 1:1 and 100% EtOAc), which yielded 24 as a pale yellow 
solid (745 mg, 49%). 
 
 











Phloroglucinol (17) (810 mg 6.42 mmol) was dissolved in DCM (8 mL) and cooled on ice 
(0 °C).  In a separate flask, AlCl3 (1.69 g, 12.7 mmol) was dissolved in DCM (10 mL) and 
cooled on ice (0 °C).  Isobutyryl chloride (0.92 mL, 9.52 mmol) was added dropwise with 
a syringe.  The resulting mixture was allowed to stir under N2 for 1 h.  This mixture was 
then added slowly to the phloroglucinol solution.  The reaction mixture was removed from 
the ice bath and set aside.  Once room temperature was reached the reaction mixture was 
stirred for a further 16 h before being quenched by the addition of 1 M HCl (15 mL) and 
dist. H2O (10 mL).  The reaction products were extracted with DCM (1 x 20 mL) followed 
by EtOAc (3 x 30 mL).  All organic fractions were combined, washed with sat. NaHCO3 
(3 x 30 mL), dist. H2O (3 x 30 mL) and brine (3 x 30 mL), dried over MgSO4 and 
concentrated in vacuo.  The concentrated fraction was purified on a 2 mmchromatotron 
plate, eluting with progressively polar solvent systems: Hex:EtoAc 9:1, Hex:EtOAc 6:1, 
Hex:EtOAc 1:1 and 100% EtOAc.  2-Methyl-1-(2,4,6-trihydroxyphenyl)propan-1-one  
(26) was obtained as a pale pink solid (493 mg, 36%).   
UV (MeOH) λmax (log ε):   229 (4.60), 287 (4.73) nm;  IR νmax:  3187, 2975, 1570, 
1515 cm-1;  1H NMR (CD3OD, 400 MHz): δH 1.12 (6H, d, J = 6.7 Hz, H-3, H-4), 3.97 (1H, 
heptet, J = 6.7 Hz, H-2), 5.82 (2H, s, H-3’, H-5’);  13C NMR (CD3OD, 400 MHz):  δC 19.8 
(C-3, C-4), 40.0 (C-2), 96.1 (C-3’, C-6’), 104.8 (C-1’) 165.8 (C-2’, C-4’, C-6’), 211.9 




Phloroglucinol (17) (820 mg, 6.50 mmol) and AlCl3 (3.36 g, 25.2 mmol) were dissolved in 
nitrobenzene (15 mL) and allowed to stir at room tep rature for 30 min.  Isobutyryl 
chloride (0.92 mL, 9.52 mmol) was added with a syringe and the resulting mixture was 
heated to 80 °C.  The reaction mixture was quenched after 1 h by adding 1 M HCl (15 mL) 
and dist. H2O (10 mL).  The reaction products were extracted with EtOAc (3 x 30 mL), 
organic fractions combined and washed with sat. NaHCO3 (3 x 30 mL), dist. H2O 
(3 x 30 mL) and brine (3 x 30 mL).  The EtOAc fraction was then dried and concentrated.  
The concentrated fraction was purified on two 4 mm chromatotron plates, eluting with 
progressively polar solvent systems: Hex:EtOAc (9:1), Hex:EtOAc (6:1), Hex:EtOAc 
(3:1), Hex:EtOAc (1:1) and 100% EtOAc.  The collected fractions were combined 
appropriately and the desired product 26 was obtained in 66% yield (848 mg). 
 










Phloroglucinol (17) (395 mg 3.13 mmol) was dissolved in DCM (8 mL) and cooled on ice 
(0 °C).  In a separate flask, AlCl3 (850 mg, 6.38 mmol) was dissolved in DCM (10 mL) 
and cooled on ice (0 °C).  2-Methylbutyryl chloride (0.39 mL, 3.17 mmol) was added 
dropwise with a syringe.  The resulting mixture was allowed to stir under N2 for 1 h.  This 
mixture was then added slowly (dropwise) to the phloroglucinol solution.  The reaction 
mixture was removed from the ice bath and set aside.  Once room temperature was reached 
the reaction mixture was stirred for a further 15 h before being quenched by the addition of 
1 M HCl (10 mL) and dist. H2O (10 mL).  The reaction products were extracted with DCM 
(1 x 20 ml) followed by EtOAc (3 x 30 mL).  All organic fractions were combined, washed 
with sat. NaHCO3 (3 x 30 mL), dist. H2O (3 x 30 mL) and brine (3 x 30 mL), dried and 
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concentrated in vacuo.  The concentrated fraction was purified on a 2 mmchromatotron 
plate (Hex:EtoAc 6:1 followed by 100% EtOAc), yielding 25 (298 mg, 45%).   
UV (MeOH) λmax (log ε):  228 (4.52), 288 (4.68) nm;  IR νmax:  3206, 2975, 1567 cm-1;  
1H NMR (CD3OD, 400 MHz): δH 0.89 (3H, t, J = 7.4 Hz, H-4), 1.10 (3H, d, J = 6.7 Hz, 
H-5), 1.36 (1H, m, H-3), 1.80 (1H, m, H-3), 3.85 (1H, sextet, J = 6.7 Hz, H-2), 5.81 (2H, s, 
H-3’, H-5’);  13C NMR (CD3OD, 400 MHz):  δC 12.5 (C-4), 17.3 (C-5), 28.3 (C-3), 46.8 
(C-2), 96.1 (C-3’, C-5’), 105.5 (C-1’), 166.0 (C-2’, C-4’, C-6’), 211.6 (C-1);  ESIMS:  
m/z 211.0968 [M+H]+ (calculated for C11H15O4, 211.0970). 
Method 2 
 
Phloroglucinol (17) (400 mg, 3.17 mmol) and AlCl3 (1.73 g, 12.9 mmol) were dissolved in 
nitrobenzene (8 mL) and allowed to stir at room temp rature for 30 min.  2-Methylbutyryl 
chloride (0.39 mL, 3.17 mmol) was added with a syringe and the resulting mixture was 
heated to 60 °C.  The reaction mixture was quenched after 2 h by adding 1 M HCl (15 mL) 
and dist. H2O (10 mL).  The reaction products were extracted with EtOAc (3 x 30 mL), 
organic fractions combined and washed with sat. NaHCO3 (3 x 30 mL), dist. H2O 
(3 x 30 mL) and brine (3 x 30 mL).  The EtOAc fraction was then dried over MgSO4 and 
concentrated in vacuo.  The concentrated fraction was purified on a 4 mmchromatotron 
plate (Hex:EtoAc 9:1, Hex:EtOAc 6:1 and 100% EtOAc).  2-Methyl-1-(2,4,6-


































2,4,6-Trihydroxybenzophenone (24) (134 mg, 0.58 mmol) and K2CO3 (166 mg, 
1.20 mmol) were dissolved in acetone (10 mL) and allowed to stir at room temperature for 
15 min.  Geranyl bromide (0.11 mL, 0.58 mmol) was injected into the vessel and the 
reaction mixture was heated until gently refluxing (60 °C).  The reaction was quenched 
after 46 h by adding 1 M HCl (20 mL).  The reaction products were extracted with EtOAc 
(3 x 30 mL), organic fractions were combined, dried and concentrated.  Purification was 
carried out on a 2 mm chromatotron plate eluting with progressively polar solvent systems:  
Hex:EtOAc 9:1, Hex:EtOAc 6:1, Hex:EtOAc 3:1, Hex:EtOAc 1:1 and 100% EtOAc.  The 
C-alkylated product, 3-geranyl-2,4,6-trihydroxybenzophenone (2) was obtained in a low 
yield of 6% (12 mg).  UV (MeOH) λmax (log ε):  310 (4.41) nm;  1H NMR (CD3OD, 
400 MHz): δH 1.56 (3H, s, H-10”), 1.61 (3H, s, H-8”), 1.76 (3H, s, H-9”), 1.96 (2H, m, 
H-4”), 2.05 (2H, m, H-5”), 3.24 (2H, d, J = 7.0 Hz, H-1”), 5.06 (1H, t, J = 7.0 Hz, H-6”), 
5.23 (1H, t, J = 7.0 Hz, H-2”), 5.88 (1H, s, H-5), 7.35 (2H, t, J = 7.4 Hz, H-4’, H-6’), 7.42 
(1H, t, J = 7.4 Hz, H-5’), 7.50 (2H, d, J = 7.4 Hz, H-3’, H-7’);  13C NMR (CD3OD, 
400 MHz):  δC 16.4 (C-9”), 17.9 (C-10”), 22.4 (C-1”), 26.0 (C-8”), 27.9 (C-5”), 41.1 
(C-4”), 95.5 (C-5), 105.6 (C-1), 108.5 (C-3), 124.6 (C-2”), 125.7 (C-6”), 128.7 (C-4’, 
C-6’), 129.3 (C-3’, C-7’), 131.8 (C-5’), 132.1 (C-7”), 135.1 (C-3”), 143.7 (C-2’), 160.7 
(C-6), 163.5 (C-4), 164.4 (C-2), 201.2 (C-1’);  ESIMS:  m/z 389.1733 [M+Na]+ (calculated 
for C23H26O4Na, 389.1729). 
 
The O-alkylated product was also isolated as the major pr duct in 12% yield (26 mg).  
1H NMR (CD3OD, 400 MHz): δH 1.59 (3H, s, H-10”), 1.61 (3H, s, H-8”), 1.66 (3H, s, 
H-9”), 1.87 (2H, m, H-4”), 1.96 (2H, m, H-5”), 4.26 (2H, d, J = 6.5 Hz, H-1”), 4.73 (1H, t, 
J = 6.5 Hz, H-6”), 5.02 (1H, t, J = 6.8 Hz, H-2”), 5.94 (1H, d, J = 2.1 Hz), 5.99 (1H, d, 
J = 2.1 Hz), 7.46 (5H, m, H-3’ – H-7’);  13C NMR (CD3OD, 400 MHz):  δC 16.8 (C-9”), 
17.9 (C-10”), 26.0 (C-8”), 27.4 (C-5”), 40.5 (C-4”), 66.3 (C-1”), 93.6 (C-5), 96.9 (C-3), 
107.2 (C-1), 120.0 (C-6”), 125.1 (C-2”), 128.8 – 129.1 (C-3’ - C-7’), 132.2 (C-7”), 132.6 






2,4,6-Trihydroxybenzophenone (24) (196 mg, 0.85 mmol) and AlCl3 (452 mg, 3.39 mmol) 
were dissolved in nitrobenzene (15 mL) and allowed to stir at room temperature for 
30 min.  Geranyl bromide (0.25 mL, 1.30 mmol) was injected into the vessel and the 
reaction mixture was heated (80 - 100 °C).  The reaction was quenched after 42 h by 
adding 1 M HCl (20 mL).  The reaction products were xtracted with EtOAc (3 x 30 mL), 
organic fractions were combined, dried and concentrated.  Purification was carried out on a 
4 mm chromatotron plate eluting with progressively polar solvent systems:  
Hex:EtOAc 9:1, Hex:EtOAc 6:1, Hex:EtOAc 3:1, Hex:EtOAc 1:1 and 100% EtOAc. NMR 





2,4,6-Trihydroxybenzophenone (24) (146 mg, 0.63 mmol) and NaH (46 mg, 1.92 mmol) 
were dissolved in dioxane (10 mL).  The reaction mixture was heated to 60 °C and allowed 
to stir for 30 min before geranyl bromide (0.19 ml, 0.98 mmol) was added.  The reaction 
was stirred for a further 3.5 h, after which it was quenched with dist. H2O (10 mL).  The 
reaction products were extracted with EtOAc, dried an  concentrated.  Purification on a 
2 mm chromatotron plate (Hex:EtOAC 9:1, Hex:EtOAc 4:1, Hex:EtOAc 2:1, 
Hex:EtOAc 1:1 and 100% EtOAc), which afforded the desired product, 3-geranyl-2,4,6-
trihydroxybenzophenone (2) (40 mg, 17%).  
 















2,4,6-Trihydroxybenzophenone (24) (253 mg, 1.10 mmol) and K2CO3 (320 mg, 
2.32 mmol) were dissolved in acetone (15 mL) and allowed to stir at room temperature for 
30 min.  Prenyl bromide (0.13 mL, 0.87 mmol) was injected into the vessel and the 
reaction mixture was heated until gently refluxing (60 °C).  Monitoring by TLC showed no 
sign of C-alkylation having occurred after a time period of 23 h, thus the temperature was 
increased to 80 °C.  The reaction was quenched after 48 h by adding 1 M HCl (20 mL).  
The reaction products were extracted with EtOAc (3 x 0 mL), organic fractions were 
combined, dried and concentrated.  Purification wascarried out on a 2 mm chromatotron 
plate eluting with progressively polar solvent systems:  Hex:EtOAc 9:1, Hex:EtOAc 7:1, 
Hex:EtOAc 3:1, Hex:EtOAc 1:1 and 100% EtOAc.  This reaction was unsuccessful as the 





2,4,6-Trihydroxybenzophenone (24) (198 mg, 0.86 mmol) and AlCl3 (456 mg, 3.42 mmol) 
were dissolved in nitrobenzene (15 mL) and allowed to stir at room temperature for 
30 min.  Prenyl bromide (0.15 mL, 1.30 mmol) was injected into the vessel and the 
reaction mixture was heated (80 - 100 °C).  The reaction was quenched after 42 h by 
adding 1 M HCl (10 mL).  The reaction products were xtracted with EtOAc (3 x 30 mL); 
organic fractions were combined, dried and concentrated in vacuo.  Column 
chromatography (diameter: 3 cm, silica height: 15 cm, loaded as a slurry, eluted with 
progressively polar solvent systems:  Hex:EtOAc 9:1, Hex:EtOAc 6:1, Hex:EtOAc 3:1, 
Hex:EtOAc 1:1 and 100% EtOAc) was used to purify the concentrated organic fraction.   





2,4,6-Trihydroxybenzophenone (24) (199 mg, 0.86 mmol) and NaH (63 mg, 1.96 mmol) 
were dissolved in dioxane (10 mL).  The reaction mixture was heated to 60 °C and allowed 
to stir for 30 min before prenyl bromide (0.15 mL, 1.30 mmol) was added.  The reaction 
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was stirred for a further 3.5 h, after which it was quenched with dist. H2O (10 mL).  The 
reaction products were extracted with EtOAc, dried and concentrated.  Purification was 
performed on a 2 mm chromatotron plate, eluting with Hex:EtOAC (9:1), 
Hex:EtOAc (4:1), Hex:EtOAc (2:1), Hex:EtOAc (1:1) and 100% EtOAc.  2,4,6-
Trihydroxy-3-prenylbenzophenone (3) was obtained (48 mg, 19%). 
UV(MeOH) λmax (log ε):  310 (4.30) nm;  IR νmax:  3179, 2919, 1598 cm-1;  1H NMR 
(CD3OD, 400 MHz): δH 1.66 (3H, s, H-5”), 1.76 (3H, s, H-4”), 3.24 (2H, d, J = 7.2 Hz, 
H-1”), 5.24 (1H, t, J = 7.2 Hz, H-2”), 5.89 (1H, s, H-5), 7.36 (2H, t, J = 7.4 Hz, H-4’, 
H-6’), 7.42 (1H, t, J = 7.4 Hz, H-5’), 7.53 (2H, d, J = 7.4 Hz, H-3’, H-7’);  13C NMR 
(CD3OD, 400 MHz):  δC 18.0 (C-4”), 22.4 (C-1”), 26.1 (C-5”), 95.5 (C-5), 105.6 (C-1), 
108.5 (C-3), 124.6 (C-2”), 128.7 (C-4’, C-6’), 129.4 (C-3’, C-7’), 131.4 (C-5’), 131.8 
(C-3”), 143.6 (C-2’), 160.6 (C-6), 163.4 (C-4), 164.4 (C-2), 201.2 (C-1’);  ESIMS:  
m/z 321.1103 [M+Na]+ (calculated for C18H18O4Na, 321.1103). 
 
4.4.2.16    [3-(3,7-Dimethylocta-2,6-dienyl)-2,4,6-trihydroxyphenyl]-2-methylpropan- 














2-Methyl-1-(2,4,6-trihydroxyphenyl)propan-1-one (26) (152 mg, 0.78 mmol) and NaH 
(55 mg, 2.29 mmol) were dissolved in dioxane (10 mL).  The reaction mixture was heated 
to 60 °C and allowed to stir for 30 min before adding geranyl bromide (0.22 mL, 
1.15 mmol).  The reaction was stirred for a further 3.5 h before being quenched with dist. 
H2O (10 mL).  The reaction products were extracted with EtOAc, dried and concentrated.  
The remaining residue was purified on a 2 mm chromat tron plate (Hex:EtOAC 9:1, 
Hex:EtOAc 4:1, Hex:EtOAc 2:1 and 100% EtOAc), which yielded the desired product (8) 
(37 mg, 15%).  
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UV(MeOH) λmax (log ε):  290 (4.22) nm;  1H NMR (CD3OD, 400 MHz): δH 1.12 (6H, d, 
J = 6.9 Hz, H-3 , H-4), 1.54 (3H, s, H-10”), 1.60 (3H, s, H-8”), 1.73 (3H, s, H-9”), 1.93 
(2H, m, H-4”), 2.02 (2H, m, H-5”), 3.18 (2H, d, J = 7.0 Hz, H-1”), 4.00 (1H, heptet, 
J = 6.6 Hz, H-2), 5.04 (1H, t, J = 7.0 Hz, H-6”), 5.17 (1H, t, J = 7.0 Hz, H-2”), 5.89 (1H, s, 
H-5’);  13C NMR (CD3OD, 400 MHz):  δC 16.3 (C-9”), 17.8 (C-10”), 19.9 (C-3, C-4), 22.3 
(C-1”), 26.0 (C-8”), 27.8 (C-5”), 40.0 (C-2), 41.0 (C-4”), 95.1 (C-5’), 104.7 (C-1’), 108.4 
(C-3’), 124.8 (C-2”), 125.6 (C-6”), 132.1 (C-7”), 134.8 (C-3”), 161.1 (C-6’), 163.5 (C-4’), 
165.4 (C-2’), 211.9 (C-1);  ESIMS:  m/z 355.1886 [M+Na]+ (calculated for C20H28O4Na, 
355.1885). 
 













2-Methyl-1-(2,4,6-trihydroxyphenyl)propan-1-one (26) (210 mg, 1.07 mmol) and NaH 
(75 mg, 3.13 mmol) was dissolved in dioxane (10 mL).  The reaction mixture was allowed 
to stir for 30 min at 60 °C.  Prenyl bromide (0.18 mL, 1.53 mmol) was added an the 
resulting mixture was stirred for a further 4 hr.  The reaction was quenched after this time 
period with dist. H2O (10 mL).  The reaction products were extracted with EtOAc 
(2 x 30 mL); organic fractions were combined, dried and concentrated.   The remaining 
residue was purified on a 2 mm chromatotron plate eluted with: Hex:EtOAc (9:1), 
Hex:EtOAc (4:1), Hex:EtOAc (2:1), Hex:EtOAc (1:1), 100% EtOAc.  The desired product  
9 was obtained in a yield of 10% (29 mg).  
UV(MeOH) λmax (log ε):  291 (4.08) nm;  IR νmax:  3426, 3324, 2975, 2916, 1599 cm-1;  
1H NMR (CD3OD, 400 MHz): δH 1.12 (6H, d, J = 6.9 Hz, H-3 , H-4), 1.64 (3H, s, H-5”), 
1.73 (3H, s, H-4”), 3.17 (2H, d, J = 7.0 Hz, H-1”), 4.00 (1H, heptet, J = 6.7 Hz, H-2), 5.17 
(1H, t, J = 7.0 Hz, H-2”), 5.89 (1H, s, H-5’);  13C NMR (CD3OD, 400 MHz):  δc 18.0 
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(C-4”), 19.9 (C-3, C-4) 22.3 (C-1”), 26.1 (C-5”), 40.1 (C-2), 95.1 (C-5’), 104.7 (C-1’), 
108.3 (C-3’), 124.8 (C-2”), 131.2 (C-3”), 161.2 (C-6’), 163.6 (C-4’), 165.5 (C-2’), 211.9 


















2-Methyl-1-[2,4,6-trihydroxyphenyl)butan-1-one (25) (155 mg, 0.74 mmol) and NaH 
(51 mg, 2.14 mmol) were dissolved in dioxane (10 mL).  The reaction mixture was heated 
to 60 °C and allowed to stir for 30 min before geranyl bromide (0.17 mL, 1.43 mmol) was 
added.  The reaction mixture was stirred for a further 3.5 h before being quenched with 
dist. H2O (10 mL).  The reaction products were extracted with EtOAc, dried and 
concentrated.  The remaining residue was purified on a 2 mm chromatotron plate, eluting 
with Hex:EtOAC 9:1, Hex:EtOAc 4:1, Hex:EtOAc 2:1 and 100% EtOAc.     The desired 
product (6) was obtained in 17% yield (44 mg). UV (MeOH) λmax (log ε):  291 (3.98) nm;  
1H NMR (CD3OD, 400 MHz): δH 0.89 (3H, t, J = 7.4 Hz, H-4), 1.10 (3H, d, J = 6.7 Hz, 
H-5), 1.36 (1H, m, H-3), 1.54 (3H, s, H-10”), 1.60 (3H, s, H-8”), 1.73 (3H, s, H-9”), 1.80 
(1H, m, H-3), 1.93 (2H, m, H-4”), 2.02 (2H, m, H-5”), 3.18 (2H, d, J = 7.0 Hz, H-1”), 3.88 
(1H, sextet, J = 6.7 Hz, H-2), 5.03 (1H, t, J = 7.4 Hz, H-6”), 5.17 (1H, t, J = 7.4 Hz, H-2”), 
5.90 (1H, s, H-5’) ;  13C NMR (CD3OD, 400 MHz):  δC 12.5 (C-4), 16.3 (C-9”), 17.4 (C-5), 
17.9 (C-10”), 22.2 (C-1”), 26.0 (C-8”), 27.8 (C-5”), 28.3 (C-3), 41.0 (C-4”), 46.8 (C-2), 
95.3 (C-5’), 124.8 (C-2”), 125.7 (C-6”), 132.1 (C-7”), 134.9 (C-3”), 165.3 (C-2’);  ESIMS:  
m/z 369.2044 [M+Na]+ (calculated for C21H30O4Na, 369.2042). 
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2-Methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one (25) (210 mg, 1.00 mmol) and NaH 
(69 mg, 2.85 mmol) were dissolved in dioxane (10 mL).  The reaction mixture was heated 
to 60 °C and allowed to stir for 30 min before prenyl bromide (0.17 mL, 1.43 mmol) was 
added.  The reaction was stirred for a further 3.5 h before being quenched with dist. H2O 
(10 mL).  The reaction products were extracted with E OAc, dried and concentrated.  The 
remaining residue was purified on a 2 mm chromatotron plate, eluting with Hex:EtOAC 
9:1, Hex:EtOAc 4:1, Hex:EtOAc 2:1 and 100% EtOAc.   The desired product 7 was 
obtained in 13% yield (36 mg).  
UV(MeOH) λmax (log ε):  292 (4.55) nm;  1H NMR (CD3OD, 400 MHz): δH 0.89 (3H, t, 
J = 7.4 Hz, H-4), 1.10 (3H, d, J = 6.8 Hz, H-5), 1.35 (1H, m, H-3), 1.64 (3H, s, H-5”), 1.73 
(3H, s, H-4”), 1.80 (1H, m, H-3), 3.17 (2H, d, J = 7.0 Hz, H-1”), 3.88 (1H, sextet, 
J = 6.8 Hz, H-2), 5.17 (1H, t, J = 7.0 Hz, H-2”), 5.88 (1H, s, H-5’);  13C NMR (CD3OD, 
400 MHz):  δC 12.5 (C-4), 17.4 (C-5), 18.0 (C-4”), 22.4 (C-1”), 26.1 (C-5”), 28.4 (C-3), 
46.8 (C-2), 95.2 (C-5’), 105.4 (C-1’), 108.3 (C-3’), 124.7 (C-2”), 131.3 (C-3”), 161.2 
(C-6’), 163.5 (C-4’), 165.4 (C-2’), 211.7 (C-1);  ESIMS:  m/z 301.1417 [M+Na]+ 
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5.1   Conclusions and Future Work 
 
The research presented in this dissertation combined natural product chemistry with 
organic synthesis.  The phytochemical investigation of the aerial plant material of the 
South African species, Hypericum roeperianum, lead to the identification of two secondary 
metabolites.  The isolated compounds, 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-phenyl-
4H-pyran-4-one (38) (hyperanone A) and {[3-(3,7-dimethyl-octa-2,6-dienyl)-2,4,6-
trihydroxyphenyl]phenylmethanone} (2), have been previously isolated from other plant 
sources.1,2,3,4,5,6 A third compound was also isolated and is provisionally assigned as 1-
methoxy-5,5-dimethyl-1-phenylhepta-1,6-diene-3,4-dione (39). However, the small 
amount of compound isolated did not provide sufficient data for a conclusive structural 
assignment.  Future work could therefore include the synthesis of compound 39 in order to 
prove that the suggested structure of the compound is correct.  To the best of our 
knowledge compound 39 has not been previously isolated. 
 
In this study, 3-geranyl-2,4,6-trihydroxybenzophenone (2) was isolated for the first time 
from the Hypericum genus, although it has been isolated previously from other species 
belonging to the Clusiaceae/Guttiferae family, namely Garcinia vieillardii, Tovomita 
krukovii and T. longifolia.2,5,6  Various inhibitory effects are exhibited by compound 2, of 
which the antimicrobial activity against Mycobaterium smegmatus i  of great interest, as 
this bacterium belongs to the same genus as Mycobaterium tuberculosis, which is the 
bacterium that is the cause of tuberculosis (TB).  Further investigation of this compound or 
compounds with related structures may therefore lead to the discovery of a potential drug 
for the treatment of tuberculosis.  Hence, the synthetic section of our research incorporated 




Synthesis of the bioactive compound 2 and the structural analogues thereof (3 – 9) were 
successfully achieved.  If significant biological activity is exhibited by one or more of our 
synthesized analogues, future work would need to include an attempt to increase the yields 
as well as an investigation of the cytotoxicity of the compounds of interest.  An increase in 
yields may be achieved by optimizing the reaction cditions of the direct C-alkylation 
method by which the analogues were produced or investigation into alternative routes may 
be considered.  Although the carcinogenic nature of the MOM protecting group needs to be 
taken into account, as well as the fact that it is no longer commercially available, it may be 
interesting to synthesise MOMCl and hence attempt the C-prenylation via O-alkylation 
followed by the Claisen rearrangement as good yields were obtained by Tan et al.7 
following this route.  The MOM protecting group is also known to be a good ortho 
directing group.  Another potential method involves alkylating via a direct ortho 
metallation (DOM) type reaction as discussed in Section 4.2.1. 
 
A literature search revealed no synthetic routes to compounds 6 and 7; we therefore believe 
that this is the first report where compounds 6 and 7 have been achieved by synthetic 
procedures.  Biological activity and toxicity testing is currently being carried out on our 
battery of eight synthetic compounds.  Future work would thus involve the evaluation of 
the results obtained in order to draw some conclusions on the structure-activity 
relationships of the various groups present in our molecules, and hence determine whether 
further investigation of these molecules as anti-tuberculosis drugs could potentially lead to 
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NMR Spectra of Isolated Compounds 
 
Plate 1.1 1H NMR spectrum (CDCl3) of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-   
phenyl-4H-pyran-4-one (38)  
Plate 1.2 13C NMR spectrum (CDCl3) of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-
phenyl-4H-pyran-4-one (38) 
Plate 1.3 DEPT90 spectrum (CDCl3) of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-
phenyl-4H-pyran-4-one (38) 
Plate 1.4 DEPT135 spectrum (CDCl3) of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-
phenyl-4H-pyran-4-one (38) 
Plate 1.5 COSY spectrum (CDCl3) of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-
phenyl-4H-pyran-4-one (38) 
Plate 1.6 HSQC spectrum (CDCl3) of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-
phenyl-4H-pyran-4-one (38) 
Plate 1.7 HMBC spectrum (CDCl3) of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-
phenyl-4H-pyran-4-one (38) 
 
Plate 2.1 1H NMR spectrum (CDCl3) of 1-Methoxy-5,5-dimethyl-1-phenylhepta-1,6-
diene-3,4-dione (39)  
Plate 2.2 13C NMR spectrum (CDCl3) of 1-Methoxy-5,5-dimethyl-1-phenylhepta-1,6-
diene-3,4-dione (39)  
Plate 2.3 DEPT90 spectrum (CDCl3) of 1-Methoxy-5,5-dimethyl-1-phenylhepta-1,6-
diene-3,4-dione (39)  
Plate 2.4 DEPT135 spectrum (CDCl3) of 1-Methoxy-5,5-dimethyl-1-phenylhepta-
1,6-diene-3,4-dione (39)  
Plate 2.5 COSY spectrum (CDCl3) of 1-Methoxy-5,5-dimethyl-1-phenylhepta-1,6-
diene-3,4-dione (39)  
Plate 2.6 HSQC spectrum (CDCl3) of 1-Methoxy-5,5-dimethyl-1-phenylhepta-1,6-
diene-3,4-dione (39)  
Plate 2.7 HMBC spectrum (CDCl3) of 1-Methoxy-5,5-dimethyl-1-phenylhepta-1,6-
diene-3,4-dione (39)  
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Plate 3.1 1H NMR spectrum (CDCl3) of 3-Geranyl-2,4,6-trihydroxybenzophenone (2)  
Plate 3.2 13C NMR spectrum (CDCl3) of 3-Geranyl-2,4,6-trihydroxybenzophenone 
(2)  
Plate 3.3 DEPT90 spectrum (CDCl3) of 3-Geranyl-2,4,6-trihydroxybenzophenone (2)  
Plate 3.4 DEPT135 spectrum (CDCl3) of 3-Geranyl-2,4,6-trihydroxybenzophenone 
(2)  
Plate 3.5 COSY spectrum (CDCl3) of 3-Geranyl-2,4,6-trihydroxybenzophenone (2)  
Plate 3.6 HSQC spectrum (CDCl3) of 3-Geranyl-2,4,6-trihydroxybenzophenone (2)  
Plate 3.7 HMBC spectrum (CDCl3) of 3-Geranyl-2,4,6-trihydroxybenzophenone (2)  
 
NMR Spectra of Synthesized Compounds 
 
Plate 4.1 1H NMR spectrum (CD3OD) of 1-[2,4-Bisbenzyloxy-6-hydroxy-3-(3-
methylbut-2-enyl)phenyl]ethanone (46) and 1-[4,6-bis-benzyloxy-3-(1,1-
dimethyl allyl)-2-hydroxyphenyl]ethanone (47) 
Plate 4.2 13C NMR spectrum (CD3OD) of 1-[2,4-Bisbenzyloxy-6-hydroxy-3-(3- 
methylbut-2-enyl)phenyl]ethanone (46) and 1-[4,6-bis-benzyloxy-3-(1,1-
dimethyl allyl)-2-hydroxyphenyl]ethanone (47) 
 
Plate 5.1 1H NMR spectrum (CD3OD) of Phenyl-(2,4,6-trihydroxyphenyl)methanone 
(24) 
Plate 5.2 13C NMR spectrum (CD3OD) of Phenyl-(2,4,6-trihydroxyphenyl) 
methanone(24) 
 
Plate 6.1 1H NMR spectrum (CD3OD) of 2-methyl-1-(2,4,6-trihydroxyphenyl)butan-
1-one (25) 
Plate 6.2 13C NMR spectrum (CD3OD) of 2-methyl-1-(2,4,6-trihydroxyphenyl)butan-
1-one (25) 
 
Plate 7.1 1H NMR spectrum (CD3OD) of 2-methyl-1-(2,4,6-trihydroxyphenyl) 
propan-1-one (26) 




Plate 8.1 1H NMR spectrum (CD3OD) of [3-(3,7-Dimethyl-octa-2,6-dienyl)-2,4,6-
trihydroxyphenyl]phenylmethanone (2) 
Plate 8.2 13C NMR spectrum (CD3OD) of [3-(3,7-Dimethyl-octa-2,6-dienyl)-2,4,6-
trihydroxyphenyl]phenylmethanone (2) 
 
Plate 9.1 1H NMR spectrum (CD3OD) of Phenyl-[2,4,6-trihydroxyphenyl)methanone  
(3) 
Plate 9.2 13C NMR spectrum (CD3OD) of Phenyl-[2,4,6-trihydroxyphenyl) 
methanone (3) 
 
Plate 10.1 1H NMR spectrum (CD3OD) of 1-[3-(3,7-Dimethyl-octa-2,6-dienyl)-2,4,6-
trihydroxyphenyl]ethanone (4) 
Plate 10.2 13C NMR spectrum (CD3OD) of 1-[3-(3,7-Dimethyl-octa-2,6-dienyl)-2,4,6-
trihydroxyphenyl]ethanone (4) 
 
Plate 11.1 1H NMR spectrum (CD3OD) of 1-[2,4,6-Trihydroxy-3-(3-methylbut-2-
enyl)pheny]lethanone (5) 
Plate 11.2 13C NMR spectrum (CD3OD) of 1-[2,4,6-Trihydroxy-3-(3-methylbut-2-
enyl)pheny]lethanone (5) 
 
Plate 12.1 1H NMR spectrum (CD3OD) of 2-Methyl-1-[2,4,6-trihydroxy-3-(3-
methylbut-2-enyl)phenyl]butan-1-one (7) 
Plate 12.2 13C NMR spectrum (CD3OD) of 2-Methyl-1-[2,4,6-trihydroxy-3-(3-
methylbut-2-enyl)phenyl]butan-1-one (7) 
 
Plate 13.1 1H NMR spectrum (CD3OD) of 2-methyl-1-[2,4,6-trihydroxy-3-(3-
methylbut-2-enyl)phenyl]propan-1-one (9) 
Plate 13.2 13C NMR spectrum (CD3OD) of 2-methyl-1-[2,4,6-trihydroxy-3-(3-
methylbut-2-enyl)phenyl]propan-1-one (9) 
 
Plate 14.1 1H NMR spectrum (CD3OD) of 1-[3-(3,7-Dimethylocta-2,6-dienyl)-2,4,6-
trihydroxyphenyl]-2-methylbutan-1-one (6) 
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Plate 15.1 1H NMR spectrum (CD3OD) of [3-(3,7-Dimethyl-octa-2,6-dienyl)-2,4,6-
trihydroxyphenyl]-2-methylpropan-1-one (8) 


















































































































































































































Plate 1.2 13C NMR spectrum (CDCl3) of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-phenyl-4H-pyran-4-one (38) 
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Plate 1.3 DEPT90 spectrum (CDCl3) of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-phenyl-4H-pyran-4-one (38) 
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Plate 1.4 DEPT135 spectrum (CDCl3) of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-phenyl-4H-pyran-4-one (38) 
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Plate 1.5   COSY spectrum (CDCl3) of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-phenyl-4H-pyran-4-one (38) 
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Plate 1.6 HMQC spectrum (CDCl3) of 3-(1,1-dimethyl-2-propenyl)-2-methoxy-6-phenyl-4H-pyran-4-one (38) 
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Plate 2.4 DEPT 135 spectrum (CDCl3) of 1-Methoxy-5,5-dimethyl-1-phenylhepta-1,6-diene-3,4-dione (39) 
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Plate 2.5 COSY spectrum (CDCl3) of 1-Methoxy-5,5-dimethyl-1-phenylhepta-1,6-diene-3,4-dione (39) 
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Plate 2.6 HMQC spectrum (CDCl3) of 1-Methoxy-5,5-dimethyl-1-phenylhepta-1,6-diene-3,4-dione (39) 
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Plate 3.4 DEPT 135 spectrum (CDCl3) of 3-Geranyl-2,4,6-trihydroxybenzophenone (2) 
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Plate 3.5 COSY spectrum (CDCl3) of 3-Geranyl-2,4,6-trihydroxybenzophenone (2) 
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Plate 4.1 1H NMR spectrum (CD3OD) of 1-[2,4-Bisbenzyloxy-6-hydroxy-3-(3-methylbut-2-enyl)phenyl]ethanone (46) and 1-[4,6-bis- 












Plate 4.2 13C NMR spectrum (CD3OD) of 1-[2,4-Bisbenzyloxy-6-hydroxy-3-(3-methylbut-2-enyl)phenyl]ethanone (46) and 1-[4,6-bis- 
























































































































































































































































































































































































































































Plate 10.1 1H NMR spectrum (CD3OD) of 1-[3-(3,7-Dimethyl-octa-2,6-dienyl)-2,4,6-trihydroxyphenyl]ethanone (4) 
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Plate 14.1 1H NMR spectrum (CD3OD) of 1-[3-(3,7-Dimethylocta-2,6-dienyl)-2,4,6-trihydroxyphenyl]-2-methylbutan-1-one (6) 
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Plate 15.2 13C NMR spectrum (CD3OD) of [3-(3,7-Dimethyl-octa-2,6-dienyl)-2,4,6-trihydroxyphenyl]-2-methylpropan-1-one (8) 
